The Moderating Effects Of Protective And Risk Factors On Outcomes For Behavioral Smoking Cessation Treatment by Reid, Holly
Wayne State University
Wayne State University Dissertations
1-1-2016
The Moderating Effects Of Protective And Risk
Factors On Outcomes For Behavioral Smoking
Cessation Treatment
Holly Reid
Wayne State University,
Follow this and additional works at: https://digitalcommons.wayne.edu/oa_dissertations
Part of the Clinical Psychology Commons
This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in
Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState.
Recommended Citation
Reid, Holly, "The Moderating Effects Of Protective And Risk Factors On Outcomes For Behavioral Smoking Cessation Treatment"
(2016). Wayne State University Dissertations. 1581.
https://digitalcommons.wayne.edu/oa_dissertations/1581
 
 
 
THE MODERATING EFFECTS OF PROTECTIVE AND RISK FACTORS ON 
OUTCOMES FOR BEHAVIORAL SMOKING CESSATION TREATMENT 
 
by 
HOLLY H. REID 
DISSERTATION 
Submitted to the Graduate School 
of Wayne State University,  
Detroit, Michigan 
in partial fulfillment of the requirements  
for the degree of 
DOCTOR OF PHILOSOPHY 
2016 
                                                MAJOR: PSYCHOLOGY (Clinical) 
 
                                          
  Approved By:  
 
          
                  ___________________________________ 
                                                                  Advisor                                                  Date 
 
      ___________________________________ 
       
___________________________________       
        
 ___________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© COPYRIGHT BY 
HOLLY H. REID 
2016 
All Rights Reserved 
 ii 
 
ACKNOWLEDGEMENTS 
Thank you to everyone who has provided me with support and direction over the 
past six years. To my adviser, Dr. Paul Toro, thank you for inviting me into your lab and 
teaching me how to better understand the complex challenges faced by underserved 
groups. To my research supervisor, Dr. Dave Ledgerwood, I am grateful for your 
mentorship since I joined the Tolan Park team four years ago. Thank you for inspiring 
my interest in the area of tobacco use and addictions, and for allowing me to conduct 
research through your studies. To my dissertation committee members, Drs. Emily 
Grekin and Marla Bartoi, thank you for being part of this project and this milestone in my 
graduate career. To my entire committee, I appreciate all of your thoughtfulness, 
feedback, and support; thank you for helping me think more deeply about this work that 
is so meaningful to me. 
To research assistants who are always so willing to help, Hayley Harrison, Lisa 
Sulkowski, Katie Mattison, and Ele Eggleston, thank you for all of your assistance, 
knowledge, and friendship over the years. 
To my family: Mom, Suzette, Julian, and Angela, you are my strengths. Mom, 
you have always been my loudest cheerleader, and my education would not be possible 
without your support. To my fiancé and partner, Jamey, thank you for being such a 
reassuring anchor throughout this entire process. You have shared selflessly in my 
burdens and successes, and you have been so willing to be a part of this project as if it 
were your own (second) dissertation. To my partner’s family: Anita, Jim, and Jessica, 
I’m thankful for your encouragement and kindness, and your constant flow of care 
packages filled with buckeye balls and banana bread. 
 iii 
 
TABLE OF CONTENTS 
 Acknowledgements ________________________________________ ii 
 List of Tables _____________________________________________ iv 
 List of Figures ____________________________________________ v 
 Chapter 1: Introduction _____________________________________ 1 
   Current Study _______________________________________ 11 
 Chapter 2: Method _________________________________________ 14 
  Participants _________________________________________ 14 
  Treatments _________________________________________ 16 
  Measures __________________________________________ 21 
  Analysis of Aims _____________________________________ 26 
 Chapter 3: Results _________________________________________ 30 
  Preliminary Analyses _________________________________ 30 
  Primary Analyses ____________________________________ 36 
 Chapter 4: Discussion ______________________________________ 47 
  Significant Findings ___________________________________ 48 
  Implications _________________________________________ 53 
  Limitations __________________________________________ 55 
  Directions for Future Research __________________________ 56 
  Conclusions ________________________________________ 56 
 References ______________________________________________ 79 
 Abstract _________________________________________________ 99 
 Autobiographical Statement__________________________________ 101  
 iv 
 
LIST OF TABLES 
 Table 1: Descriptive Statistics................................................................. 58 
 Table 2: Significant Bivariate Correlations .............................................. 59 
 Table 3: Hierarchical Regression Analysis for Violence and Initial  
               Smoking Cessation ................................................................... 60 
 
 Table 4: Hierarchical Regression Analysis for Violence and Total  
               Smoking Cessation ................................................................... 62 
 
 Table 5: Hierarchical Regression Analysis for Mood and Initial  
               Smoking Cessation ................................................................... 64 
 
 Table 6: Hierarchical Regression Analysis for Mood and Total  
               Smoking Cessation ................................................................... 66 
 
 Table 7: Moderating Effects of Social Support on the Relationship  
                         between Violence and Time 1 Change in Cigarette Use .......... 68 
 
 Table 8: Moderating Effects of Social Support on the Relationship  
                         between Depressive Symptoms and Time 1 Change in  
                         Withdrawal ................................................................................ 70 
 
 Table 9: Moderating Effects of Social Support on the Relationship  
               between Depressive Symptoms/Life Satisfaction and Time 1  
                        Change in Cigarette Use ........................................................... 71 
 
 Table 10: Moderating Effects of Social Support on the Relationship  
                           between Depressive Symptoms and Time 2 Change in  
                           Cigarette Use ......................................................................... 73 
 
 Table 11: Selected Item Endorsements of Community Violence Exposure  
                 on Things I Have Seen and Heard ......................................... 74 
 
 Table 12: Selected Item Endorsements of Intimate Partner Violence  
                           Victimization on Revised Conflict Tactics Scale ..................... 75 
 
 Table 13: Selected Item Endorsements of Intimate Partner Violence  
                 Perpetration on Revised Conflict Tactics Scale ...................... 76 
 
 Table 14: Mean Reports of Life Satisfaction in 17 Areas of Life  
                           Functioning ............................................................................. 77 
 v 
 
LIST OF FIGURES 
 
 Figure 1: Reductions in Nicotine Withdrawal by High/Low Depression  
                          Scores ..................................................................................... 78
1 
 
 
CHAPTER 1: INTRODUCTION 
Cigarette smoking is the chief cause of preventable death in the United States, 
accounting for one out of five deaths annually (CDC, 2014). Although 70 percent of 
smokers attempt to quit at least once in their lifetime, and 40 percent of smokers 
attempt to quit yearly, most smokers relapse to smoking within days of a quit attempt 
(CDC, 2014). People living with HIV/AIDS (PLWHA) are among a “special population” of 
smokers, identified as those with greater smoking prevalence, disproportionate tobacco-
related health disparities, and less access to treatment relative to the general population 
(Borelli, 2010). This high-risk group is also characterized by a deficit of population-
specific longitudinal treatment trials. PLWHA report significantly higher rates of cigarette 
smoking, face increased negative physical health outcomes associated with smoking, 
and experience more cessation treatment barriers than do those without HIV/AIDS 
(Burkhalter, Springer, Chhabra, Ostroff, & Rapkin, 2005; Crothers et al., 2009). The 
current study is part of the first randomized clinical trial of contingency management 
(CM) for smoking cessation among PLWHA.   
Cigarette Smoking and HIV/AIDS. Up to 70% of PLWHA report being daily 
cigarette smokers (Burkhalter et al., 2005). Smokers who are HIV positive have 
significantly increased mortality rates in addition to reduced CD4 cell counts, higher viral 
load levels (i.e., HIV RNA), less responsiveness to antiretroviral treatment, and more 
rapid progression to AIDS (Furber, Maheswaran, Newell, & Carroll, 2007). Relative to 
non-infected smokers, HIV-positive smokers have increased rates of cancer, 
respiratory, pulmonary, and bacterial illnesses, and lower life quality (Crothers et al., 
2009; Feldman et al., 2006). Importantly, quitting as well as increasing one’s duration of 
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smoking abstinence significantly reduces HIV symptom burden (Vidrine, Arduino, & 
Gritz, 2007). 
There is a strong desire among PLWHA to quit smoking. One study showed that 
63% of HIV-positive smokers want to stop smoking, and 72% have unsuccessfully 
attempted to abstain from smoking (Mamary, Bahrs, & Martinez, 2002). Almost 70% of 
these individuals expressed interest in a group intervention for smoking cessation, and 
82% of these smokers were willing to participate in nicotine replacement therapy for 
cessation. Despite this desire and motivation to discontinue tobacco use, there has 
been a lack of consistent literature confirming the efficacy of varying cessation 
treatments for HIV-positive individuals. Although pharmacological treatment trials 
centered on nicotine replacement have sometimes demonstrated higher abstinence 
rates relative to a no-treatment control (Elzi et al., 2006), others have shown low 
medication adherence (Ingersoll, Cropsey, & Heckmann, 2009) or low rates of smoking 
abstinence (Lloyd-Richardson et al., 2009). Behaviorally-based studies that aim to tailor 
to PLWHA by addressing physical treatment barriers have demonstrated some short-
term cessation effects (e.g., Vidrine, Arduino, Lazev, & Gritz, 2006); however, more 
longitudinal information is needed (Vidrine, Arduino, Lazev, & Gritz, 2012; Fjeldsoe, 
Marshall, & Miller, 2009). There is a need to continue testing randomized longitudinal 
treatment methods tailored to HIV-infected smokers. The larger randomized trial that 
houses the current study is adapted to PLWHA not only through its use of bupropion as 
a smoking cessation medication that does not interfere with antiretroviral treatment, but 
also by its modification of ongoing treatment based on the individual responses of 
participants, enhancing time and cost effectiveness.  
3 
 
 
Cigarette Smoking and Violence Exposure. Two prominent types of violence 
exposure commonly linked to psychological distress and functioning are community 
violence and intimate partner violence. Violence is commonly defined as the use of 
threatened or actual power or force against an individual or group that may result in 
injury, death, psychological harm, abnormal development, or deprivation (Dahlberg & 
Krug, 2002). Community violence exposure can be further characterized by witnessing 
or personally experiencing stabbings, muggings, shootings, murders or other assaults 
(Gorman-Smith, Henry, & Tolan, 2004). Intimate partner trauma refers to physical, 
sexual, and psychological violence enacted by previous or current spouses and dating 
partners, often occurring in the form of rape, physical assault, and stalking (CDC, 2011). 
Although more women than men report partner violence exposure, almost 30% of men 
report experiencing intimate partner violence in their lifetimes (Reid et al., 2008).  
Interpersonal trauma exposure accounts for over 500,000 deaths annually and is 
associated with significant physical, psychological, emotional, and financial burden 
(CDC, 2003). Similarly, community violence exposure is consistently linked to mortality 
in addition to social, psychological and physical affliction (World Health Organization 
[WHO], 2002). Though violence exposure does not necessarily need to be recognized 
by the victim as traumatic, individuals who undergo exposure in these forms often 
experience posttraumatic stress symptoms or develop Posttraumatic Stress Disorder 
(PTSD). Congruently, PTSD diagnoses require exposure to an event that involves 
actual or threatened death or injury (American Psychiatric Association, 2013). 
Substance use is one of the clearest correlates of these forms of violence 
victimization (Beckham et al., 2005; Calhoun, Denis, & Beckham, 2007; Feldner et al., 
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2007; Koenen et al., 2005; Morissette et al. 2007), with 90% of adults with substance 
use disorders reporting history of psychological trauma exposure (CDC, 2003). Studies 
specifically show a strong relationship between violence exposure and increased rates 
of smoking and nicotine dependence across genders and ethnicities (Buckley et al., 
2004; Dobie et al., 2004; Feldner et al., 2007; Hapke et al., 2005; Lassar et al., 2000). 
These associations are observed independent of whether the smoker meets clinical 
criteria for PTSD (Al Mamun et al., 2007; Hapke et al., 2005) and are sometimes 
stronger than the correlation between prior trauma and alcohol consumption (Breslau et 
al., 2003; Op Den Velde et al., 2002). Women who experience psychological (e.g., 
verbal) partner violence show increased risk of cigarette smoking, with even higher risk 
of use when physical or sexual abuse enacted by intimate partners is reported (Jun et 
al., 2008). Global studies additionally find that domestic violence is strongly associated 
with tobacco use cross-culturally, particularly in areas where violence against women is 
more prevalent (Ackerson, Kawachi, Barbeau, & Subramanian, 2007). Additionally, not 
only does experiencing violence increase risk of initiating cigarette use, substance use 
also reciprocally increases risk of being a victim or perpetrator of violence (Atkinson et 
al., 2009; Krug et al., 2002). There is a strong need to examine the effects of different 
modes of violence exposure on treatment outcomes and smoking abstinence.  
There are a number of conceptual models that aim to explain linkages between 
trauma and cigarette use. It is often suggested that nicotine is used to reduce the 
emotional and sometimes physical discomfort associated with trauma (e.g., Logan et 
al., 2002). Stress and coping models also explain smoking as a method of stress 
reduction, associating stress with increased urges for cigarette smoking and cyclically 
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less success in quitting smoking (Cohen & Lichtenstein, 1990; Jun, Rich-Edwards, 
Boynton-Jarrett, & Wright, 2008). Severity of nicotine dependence has been positively 
associated with avoidance, hyperarousal, and other PTSD symptoms (Thorndike, 
Wernicke, Pearlman, & Haaga, 2006), suggesting that current tobacco use may be 
related to peri-traumatic modes of tension reduction. Unsurprisingly, risk factors specific 
to quitting smoking include anxiety, which is focal to post-traumatic stress.  
Trauma exposure has also been implicated as a negative causal force on 
smoking cessation treatment outcomes (Lasser et al., 2000), likely related to the 
challenging cognitions and mood states that characteristically accompany trauma. This 
post-trauma experience may include persistent negative beliefs (e.g., “no one can be 
trusted”), distorted thought processes about the cause or outcomes of violence (e.g., 
self-blame), negative emotional states (e.g., fear, anger), difficulty experiencing positive 
emotional states, and feelings of detachment from others (APA, 2013). Survivors of 
violence are often challenged by building trust and finding purpose in life events, as well 
as by feelings of guilt, shame, lack of power, and uncertainty (Feldner, Babson, & 
Zvolensky, 2007). One study found that the severity of symptoms associated with 
witnessing violent assaults and history of emotional abuse predicted poorer retention 
and abstinence outcomes in a CM-based intervention for substance use (Ford et al., 
2007). Studies also show correlations between sexual trauma and treatment indicators 
such as lack of trust, expression of feelings, and thought processing (Rosen et al., 
2002; Sikkema, 2007).  
Violence Exposure and HIV/AIDS. Both intimate partner violence and 
community violence exposure are common among individuals living with HIV/AIDS. 
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Compared to 8.7% of the general population who report traumatic experiences, 62% of 
HIV-positive individuals have experienced trauma exposure (Matchinger, Wilson, 
Haberer, & Weiss, 2012). The experience of sexual abuse is strongly associated with 
both HIV status and broader engagement in risky sexual behaviors (Sikkema et al., 
2007), with individuals who were abused being more likely to participate in high-risk 
behaviors that increase exposure to HIV (e.g., Carballo-Dieguez & Dolezal, 1995). 
Violence against women has also specifically been linked to sexually transmitted 
infections including HIV infection (Gore-Felton, DiMarco, & Anderson, 2007). For 
example, women who are in violent and abusive relationships are more likely to 
experience abuse as a result of requesting the use of condoms, thus being less likely to 
use sexual protection (Ajuwon et al., 2001; Kalichman et al. 1998; WHO, 2014; 
Wingood & DiClemente, 1997).  
Even among healthy individuals, violence exposure is associated with increased 
engagement in risky behaviors, more somatic symptoms and fatigue, and poorer 
immune and general health function (Baroso et al., 2010). The physiological effects of 
violence exposure and post-trauma symptoms are even more highly related to health 
outcomes among PLWHA. Physical and psychological stress associated with violent 
experiences can contribute to hypothalamic-pituitary-adrenal (HPA) dysregularities that 
negatively impact disease progression, HIV processes and presentation, and general 
immunologic functioning (Biglino et al., 1995; Cole & Kemeny 1997). For example, HIV 
positive individuals are more likely to have chronic cortisol elevations (i.e., 
hypercortisolemia), which may increase viral replication (Swanson et al., 1998). 
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Violence is also linked to negative HIV-specific treatment outcomes. Interestingly, 
one study found that trauma exposure was related to poorer treatment adherence in 
black men as mediated by perceived discrimination (Wagner et al., 2012). The literature 
additionally shows linkages among past violence exposure (e.g., combat, partner 
abuse), development of PTSD from the HIV diagnosis itself, and post-diagnostic 
psychiatric distress (Kelly et al., 1998), again highlighting a need to clinically attend to 
previous trauma exposure. It has thus been suggested that HIV treatment incorporate 
trauma and domestic violence screening as a mode of reducing symptoms that may 
interfere with HIV treatment and health (Humphrey, 2014).  
Protective Factors in the Treatment of Cigarette Smoking. Though protective 
factors such as social support are related to smoking behaviors as well as health 
outcomes for PLWHA, few studies have clearly examined the role of these buffers in 
smoking treatment among this population. Further, no studies have examined 
psychosocial protective and risk factors in a CM smoking cessation treatment design. 
Social support, psychological distress, and life quality will be discussed here.  
Social Support. Several studies show that social support not only increases 
mobilization of psychological resources, but also provides tangible support such as 
money, skills, and guidance (Bao, Whitbeck, & Hoyt, 2000; Cohen & Wills, 1985; 
Maulik, Eaton, & Bradshaw, 2010). By the stress buffering model, social support 
positively influences appraisals of threat following stressful events, bolstering perceived 
ability to adequately cope with stressors. Alternatively, support can intervene after a 
stress appraisal has been made, protecting against negative outcomes by increasing 
positive reappraisals of the stressor, reducing perceived importance of the problem, or 
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providing solutions to the problem (Cohen et al., 1985). Importantly, lack of social 
support is associated with elevated smoking rates and reduced cessation (May & West, 
2000), and has been shown to be related to maladaptive, avoidant coping strategies 
among HIV-positive men (Leserman et al., 1992; Tate et al., 2006). Social support has 
congruently been found to be effective in smoking cessation treatment in the general 
nicotine-dependent population (Fiore et al., 2008). Perceived social support is also 
related to experiences of violence victimization, often buffering against negative effects 
of traumatic events among adults (Nordentoft, 2010). 
There remains a need to research the effects of social support on health and 
substance cessation among PLWHA. The limited literature on social support as a 
protective factor in the mental and physical health of HIV-positive adults is mixed 
(Ironson & Hayward, 2008). Some studies show a positive effect of social support on 
physical and mental health (Ashton et al., 2005; Leserman et al., 2002), while others 
find weak associations (e.g., Ironson et al., 2005), or suggest that support is only 
predictive of better health when individuals are in advanced stages of disease infection 
(Patterson et al., 1996).  
It is possible that there are social components specific to HIV/AIDS that separate 
the disease from other chronic medical illnesses (e.g., cancer, cardiovascular disease) 
for which social support is consistently linked to increased health. One study found that 
PLWHA who report increased social support also report more engagement in risky 
sexual behaviors (Holmes & Pace, 2002; Miller & Cole, 1998). It is also likely that 
certain groups more prevalently sampled in earlier studies (e.g., HIV-positive men who 
sleep with men) are operationally different than other HIV-positive subgroups in social 
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and social support characteristics. Additionally, social support for PLWHA may differ as 
a product of the social stigma associated with HIV status (Gostin & Webber, 1998; 
Vanable et al. 2006). In light of the social and medical complexity of HIV/AIDS, it is 
important to continue investigating the multifaceted impact of social support on PLWHA.  
Psychological Distress and Life Quality. Depression is associated with more than 
twice the risk of HIV progression to AIDS (Golub et al., 2003). Examining change in 
depressive symptoms longitudinally, the Coping in Health and Illness Project found that 
for every cumulative increase in depressive symptoms, AIDS risk doubled at 5.5 years 
(Leserman et al., 2008, 2002, 1999). Another study among women showed that 
depression measured longitudinally was associated with 61% increased risk of clinical 
progression and more than double the risk of fatality (Antelman et al., 2007). Distress 
specifically related to trauma is also instrumental in the medical health of HIV-positive 
individuals, with post-violence avoidance and intrusion being linked to more depression 
and lower CD4+ percentages (Lutgendorf et al., 1997). Depression is also heavily linked 
to nicotine dependence, withdrawal, and ability to quit smoking in the general population 
(Glassman et al., 2001; O’Brien et al., 2004). As rates of current depression are three 
times higher in HIV-positive individuals than in the general population (Ferrando & 
Freyberg, 2008; Reynolds, 2009), there is a critical need to address the role of 
depression in substance treatment for PLWHA. 
Stressful life events are also strongly related to rapid HIV disease progression. 
One early study found that for each stressful life event in a six-month period, the risk of 
early HIV disease progression doubled (Evans et al., 1997). Meta-analyses have shown 
that, along with distress and prior trauma, stressful events negatively impact HIV 
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disease progression, acting to lower CD4 T lymphocytes, and increase viral load, 
clinical decline, and mortality (Leserman, 2008). Life quality is also often linked to 
cigarette smoking, with increased smoking being related to lower life quality, and 
abstinence promoting higher life quality (Hays, Croghan, Baker, Cappelleri, & 
Bushmakin, 2012). Both depression and life quality negatively impact smoking 
cessation treatment in the general population (Cinciripini et al., 2003; Freedland et al., 
2005), though it is unclear the specific effect it has on smokers living with HIV/AIDS, 
who report significantly higher rates of psychiatric illness.  
Contingency Management. Among a growing number of interventions focused 
on reducing smoking behaviors, contingency management (CM) has demonstrated 
efficacy in improving substance cessation outcomes across several patient populations 
(e.g., Alessi et al., 2004; Dutra et al., 2008; Ledgerwood et al., 2008; Petry & Alessi, 
2010). CM is founded on the concept that voluntary behavior exists in the context of 
environmental contingencies, wherein frequency of behavior occurs in correlation with 
the desire to obtain or avoid positive or negative consequences (Skinner, 1953).  
By this theoretical approach, cigarette smoking is reinforced and maintained via 
an operant conditioning process involving the biochemical effects of nicotine as well as 
environmental reinforcers (e.g., increased social interaction; Higgins & Petry, 1999). 
Providers select a target behavior that indicates smoking abstinence (e.g., low cotinine 
levels), and offer incentives which are likely to be rewarding to the smoker. Through this 
process, behavioral principles of reinforcement operate to counteract the reinforcing 
mechanisms of chronic smoking. CM has previously been used to reduce HIV-related 
risk behaviors, such as antiretroviral medication adherence (Haug & Sorensen, 2006).  
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The present study uses prize-based CM, which was developed as an alternative 
to more costly monetary and voucher CM treatment systems (Petry et al., 2000). Rather 
than offering money or vouchers, which typically exceed maximum reinforcement 
amounts of 1,000 dollars (Higgins et al., 2004; Silverman et al., 1998), prize-based CM 
offers the opportunity to win prizes of varying magnitudes at a particular reinforcement 
schedule. Prize-based CM is an efficacious approach to the treatment of a range of 
substances (Petry et al., 2005; Pierce et al., 2006) including nicotine (Ledgerwood et al., 
2014). The larger clinical trial that houses the present study is the first to assess the 
effects of prize-based CM among PLWHA.  
Current Study 
 The present study examined how risk and protective factors impact cessation 
efforts among PLWHA undergoing contingency-based treatment for cigarette smoking. 
Specifically, this study aimed to assess (1) how community and interpersonal partner 
violence exposure affect smoking cessation among PLWHA, (2) how high depression 
and low life satisfaction affect smoking cessation among PLWHA, (3) how social 
support affects smoking cessation among PLWHA, and (4) whether social support 
moderates relationships between predictors and smoking cessation success among 
PLWHA.  
Smoking Cessation. Smoking cessation success was measured by six smoking 
indicators: (1) urinary cotinine, (2) longest duration of continuous abstinence, (3) self-
reported cigarette use, (4) self-reported change in withdrawal symptoms, (5) self-
reported change in smoking urges, and (6) self-reported change in motivations for 
quitting smoking. To better understand change in smoking cessation from pre to post-
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treatment, change scores (X-Y) were assessed from intake (X) to post-Phase 1 (Y) and 
2 (Z). Smoking cessation scores assessed following the first and second treatment 
phases were used for the current analyses. These cessation indicators are described in 
more detail in Chapter 2 (Method).  
Community and Partner Violence Exposure. Self-reported violence exposure 
scores reported at the intake assessment were used to predict cigarette use outcomes 
measured after the first and second phases of treatment. I hypothesized that both 
increased community violence and intimate partner violence exposure would be 
inversely related to smoking cessation indicators. Specifically, increased violence 
exposure will predict lower levels of abstinence, fewer days of continuous abstinence, 
greater cigarette use, greater withdrawal symptoms, more urges to smoke, and fewer 
reasons for quitting smoking. 
High Depression and Low Life Satisfaction. Depression and life satisfaction 
assessed during the intake session were used to predict post-Phase 1 and post-Phase 
2 smoking outcomes. I hypothesized that higher depression and lower life satisfaction 
would be inversely related to smoking cessation indicators. Specifically, high depression 
and low quality of life will predict lower levels of abstinence, fewer continuous days of 
abstinence, greater use frequency, greater withdrawal symptoms, more urges to smoke, 
and fewer reasons for quitting smoking. 
Social Support. Social support assesses appraisal, belonging, available help, 
and self-esteem support. A moderation model examined the effect of perceived social 
support, as self-reported in the intake assessment, on the relationship between the 
above noted predictor variables (community violence, interpersonal violence, 
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depression, and life satisfaction), and the above noted outcome variables (changes in 
cotinine, changes in use frequency, changes in withdrawal, changes in urges, changes 
in motivations for quitting smoking, and LDA). I hypothesized that social support would 
be positively related to smoking cessation indicators. Additionally, increased social 
support will moderate the relationship between increased violence exposure and 
smoking, higher depression and smoking, and lower life satisfaction and smoking, such 
that increased social support will be related to reduced smoking indicators. 
Treatment Condition. Treatment condition assignment in Phase 1 of the study 
was additionally assessed and controlled for. Treatment condition was randomly 
assigned. Phase 1 treatments are described in detail at a later point. 
Thus, this study used longitudinal data and hierarchical regressions to test four 
hypotheses: (1) increased violence exposure is related to poorer smoking cessation 
outcomes, (2) higher depression and lower life satisfaction is related to poorer smoking 
cessation outcomes, (3) social support is positively related to smoking cessation 
outcomes, and (4) social support moderates the relationship between violence history 
and smoking, depression and smoking, and life satisfaction and smoking.  
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CHAPTER 2: METHOD 
Participants 
 Participants are those who are enrolled in a larger randomized clinical trial of 
contingency management for smoking cessation among PLWHA (NIH grant R01 
DA034537-01A1; clinical trial identifier: NCT01965405). Participants are 40 daily 
cigarette smokers from the Wayne State University Physician’s Group (WSUPG) adult 
HIV/AIDS clinic located in Detroit. These individuals represent a portion of the 
participants in the larger clinical trial study. The number of participants included in the 
current study was dependent on the rate of participant recruitment and eligibility. 
Inclusion criteria are as follows: at least 18 years of age, ability to read and understand 
English, use of at least 10 cigarettes daily, and patient attendance at the WSUPG 
HIV/AIDS clinic. Exclusion criteria are as follows: active suicidality, uncontrolled manic 
or psychotic symptoms, being in recovery for pathological gambling, having 
contraindications for bupropion treatment (e.g., epilepsy, use of MAO inhibitors/other 
antidepressants, presence of eating disorders/low body mass), or participation in other 
smoking cessation interventions.  
A sequential Multiple Assignment Randomized Trial (SMART) design is used in 
the larger study. SMART utilizes a stepped-care method that tailors treatment to initial 
treatment response. Participants in Phase 1 who respond to initial brief treatment (i.e., 
reduce their smoking) received a different treatment assignment in Phase 2 than 
participants in Phase 1 who do not respond to initial treatment (i.e., do not reduce their 
smoking).  
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Participants in Phase 1 were randomized to one of two brief interventions: (1) 
counseling care and bupropion pharmacotherapy (i.e., standard of care), or (2) 
Standard of care in addition to high magnitude prize contingency management (CM). 
Treatments are described in more detail below. Upon completion of Phase 1, 
participants were classified as Responders or Non-Responders based on their smoking 
reduction or abstinence.  
Non-responders who enter Phase 2a were randomly assigned to one of two 
conditions: (1) continued counseling and monitoring support, or (2) monitoring support 
and prize CM. Phase 1 responders who enter Phase 2b were randomly assigned to one 
of two conditions: (1) no additional treatment, or (2) continued monitoring and low 
intensity prize CM. Treatments are described in more detail below. 
Random assignment to treatment conditions was balanced by gender, and 
average daily number of cigarettes smoked (< 1 pack/day, or > 1 pack/day). An urn 
randomization procedure was used to equate groups across these parameters. Random 
assignment to Phase 1 treatment conditions occurred during the initial intake (day 1 of 
treatment), and random assignment to Phase 2a and 2b treatment conditions occurred 
at the start of Phase 2, balanced in the same way as Phase 1. The present study was 
conducted in accordance with Declaration of Helsinki and was approved by the Wayne 
State University Institutional Review Board.  
The study’s stepped care design addresses criticisms of a CM-based approach 
to cessation treatment in that it aimed to be less time-intensive and more cost-effective. 
The design minimized time requirements and prize-based treatment for individuals who 
responded to brief treatment and do not require continuing CM, implementing a more 
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intensive CM schedule only for those with matching clinical need. The study additionally 
used prize-based CM in place of more costly cash or voucher-based alternatives 
(Higgins et al. 2004), reducing costs by rewarding opportunities to earn prizes of varying 
magnitude rather than using money or money-based vouchers (Petry et al., 2000, 
2005).  
Treatments 
The larger clinical trial involves two treatment phases (4 weeks, and 8 weeks 
long respectively), followed by 6 and 12-month post-treatment follow-ups. The present 
study used data from the baseline assessment, the post-Phase 1 (weeks 1-4) treatment 
assessment, and the post-Phase 2 (weeks 5-12) treatment assessment.  
Phase 1. Phase 1 spanned four weeks, and included participant randomization 
into either Standard of Care, or Standard of Care plus High-Magnitude Prize 
Contingency Management.  
Standard of Care. Standard care involved (1) monitoring of smoking cessation 
using biological indicators (urinary cotinine) and medication compliance, (2) brief 
counseling based on clinical practice guidelines (Fiore et al., 2008), and (3) bupropion 
pharmacotherapy. Participants met with the research therapist weekly for four weeks to 
provide samples and receive 15-minute counseling geared toward smoking cessation. 
Counseling was based on the 5As/Rs model.  
 The 5As/Rs approach involved the 5 As: (1) Ask about tobacco use, (2) Advise 
the participant to quit smoking, (3) Assess willingness to quit, (4) Assist in the quit 
attempt through supportive counseling, and (5) Arrange follow-up assessments (U.S. 
Public Health Service [USPHS]). The 5 Rs were used to address ambivalence about 
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quitting smoking, and are based on motivational interviewing principles. The 5 Rs are: 
(1) encourage the participant to indicate personal Relevance of quitting smoking, (2) 
have the participant identify Risks of continued tobacco use, (3) together identify 
potential Rewards of quitting smoking, (4) identify Roadblocks or barriers to quitting, 
and show how counseling may address these barriers, and (5) Repeat motivational 
interviewing at each subsequent visit. The therapist also reviewed a smoking cessation 
self-help quit guide with the participant titled You Can Quit Smoking, which emphasizes 
the importance of motivation, social support, and behavioral skills in reducing smoking 
behaviors (U.S. Department of Health and Human Services). Specifically, the guide 
addresses reasons for quitting smoking, preparing to quit, gaining social support 
specific to cessation, skills building, use of medications, and relapse prevention and 
preparation.  
 All participants, regardless of condition, were prescribed sustained release 
bupropion, which has demonstrated efficacy in smoking cessation (Hughes, Stead, 
Hartmann-Boyce, Cahill, & Lancaster, 2014), is in-line with current Standard of Care, 
and does not interfere with assessment of urinary cotinine levels. Participants received 
a flexible dosing procedure of 150 mg/day for the first three days followed by a potential 
dose increase to 300 mg/day depending on medication tolerability. The recommended 
maximum dose of bupropion for smoking is 300 mg/day, or 150 mg twice/day at 8-hour 
intervals (Aubin, 2002). The study physician prescribed bupropion and adjusted 
dosages based on clinical observation and monitoring of participant responses using 
the Bupropion Adverse Effects Checklist. Bupropion treatment continued for 12 weeks 
(Phase 1, and Phase 2a/b) with a two-week taper to 150 mg in week 11, 75 mg in week 
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12, and 0 mg at the end of week 12. Studies show that bupropion is efficacious and safe 
for treating PLWHA and those taking antiretroviral medications (Currier, Molina, & Kato, 
2003; Pedrol-Clotet et al., 2006). Bupropion administration compliance was closely 
monitored to assess differential impact on treatment outcomes among treatment 
conditions. Research assistants conducted pill counts and reviewed participant self-
reports of medication compliance.  
Standard of Care Plus High Magnitude Prize Contingency Management. 
Participants in the High Magnitude condition received the same cotinine test result 
monitoring and brief counseling procedures described above (see Standard of Care 
section, p. 16), and provided CO and cotinine samples on the same schedule. 
Participants additionally earned chances to win prizes if they met criteria for early 
smoking reduction or abstinence (Petry, 2000; Petry et al., 2004). Criteria included 
cotinine levels lower than the most recent level provided, or below the abstinence cut off 
of < 2. If the participant reduced their cotinine score, but then lapsed, the participant had 
to reduce subsequent cotinine levels from the point of the lapse to regain a chance for 
reinforcement. Presenting with a cotinine level above the cutoff, refusing to provide a 
sample, or being absent without excuse (e.g., illness, family emergency) resulted in 
draws being reset to one draw for the next provided negative sample. Participants 
earned draws from the prize-bowl during each weekly session in which they met the 
reduction/abstinence criteria. In each of weeks 2-4 of treatment, when participants 
reduce scores from the previous week, they earn one additional draw. That is, reducing 
smoking at the week 2 session earns the participant two draws; reducing smoking at 
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week 3 earns the participant three draws, et cetera. By the end of the fourth treatment 
week, participants may earn up to a total of 10 draws.  
 The prize urn for Phase 1 of treatment included 50 slips of paper with the 
following breakdown: 60% (30 slips) result in a large prize ($20); 30% (15 slips) result in 
a super prize ($50); 10% (5) result in a jumbo prize ($100). Participants may earn an 
average maximum of $370 in reinforcement if they abstain from smoking throughout this 
phase.   
Phase 2. Phase 2a assigned treatment non-responders from Phase 1 to one of 
two conditions: (1) continued counseling and monitoring, or (2) continued counseling 
plus 8-week prize CM. Phase 2b assigned treatment responders from Phase 1 to one of 
two conditions: (1) no additional intervention, consistent with standard of care, or (2) 
continued counseling and monitoring, and 8-week low-magnitude prize CM. Phase 2a 
and 2b treatments are described in more detail below. 
Treatment non-responders were classified as those who continued to smoke at 
levels similar to baseline at the conclusion of Phase 1, determined by objective 
indicators of smoking: (1) urinary cotinine levels that are not reduced from baseline (i.e., 
< 2 points pre to post change), or (2) expired CO levels that are not significantly 
reduced (i.e., > 3 ppm on the final day of testing). Treatment responders were classified 
as those who significantly reduced smoking as defined by cotinine levels substantially 
lower than baseline scores (> 2 point reduction), or abstinence based on expired CO at 
the final visit (< 3 ppm). The cut-off of < 3 ppm has demonstrated high sensitivity and 
specificity for abstinence (e.g., Javors, Hatch, & Lamb, 2004). As cotinine has a longer 
half-life relative to that of CO (20 hours versus four hours for CO; Benowitz & Jacob, 
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1997), a reduction score of > 2 points was chosen as an indicator of recent treatment 
responsiveness.  
Phase 2a. All non-responders continued to receive medical monitoring of 
bupropion for 8 additional treatment weeks, in addition to the randomly assigned 
treatment. 
Counseling and Monitoring of Smoking (MS). Participants met with the study 
therapists twice weekly to review smoking cessation progress, provide breath samples 
for CO testing, and provide urine samples for weekly cotinine testing. Therapists 
provided support and encouragement as well as results of weekly testing. 
MS Plus Contingency Management (MS+CM). Participants received the 
treatment as MS treatment participants, in addition to prize CM for abstinence, weekly 
for 8 weeks. The method for prize drawing was similar to that of Phase 1; thus, 
participants received prize draws during weekly therapist meetings if cotinine levels 
were lower than the most recent level previously provided, or levels were below or at 
the absolute cutoff of 2. Participants received one draw on the first day of treatment, 
with escalating draws at each consecutive, negative cotinine test up to a total of 10 
draws on a given day. Once the participant earned the maximum number of draws, the 
participant received that number of draws at each subsequent negative cotinine 
reading. The same reset contingencies as described in Phase 1 were used; however, 
resets were reversed once the participant reached three consecutive, negative samples 
(i.e., the number of prizes will be restored to the highest achieved level pre-reset). 
Additionally, every third consecutive test that met reinforcement criteria earned the 
participant five bonus draws. Phase 2 reset contingencies are dissimilar to the Phase 1 
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reset protocol solely because there were not enough testing sessions in Phase 1 to 
restore resets. 
The prize urn for Phase 2 of treatment included 500 slips of paper with the 
following breakdown: 50% (250 slips) result in no prize (e.g., “Good job!”); 42.6% (213 
slips) result in a small prize ($2); 7% (35 slips) result in a large prize ($20); .4% (2 slips) 
result in a jumbo prize ($100). Participants may earn up to 115 draws plus 25 bonus 
draws over the eight-week treatment period, with an average maximum value of $371 in 
prize reinforcement.  
Phase 2b. Similar to Phase 2a (non-responder) treatments, all responders 
continued to receive medical monitoring of bupropion treatment for 8 treatment weeks, 
in addition to randomly assigned Phase 2 conditions.  
No Additional Treatment (NAT). Participants received no additional treatment of 
smoking monitoring following Phase 1, consistent with SoC methods that followed brief 
treatment and medication administration. NAT participants were contacted for follow-up 
assessments only. 
Counseling and Monitoring of Smoking Plus Low Intensity Prize CM. Participants 
received the same counseling and monitoring as described in 2a treatments, with less 
frequency. Participants met with research therapists weekly for four weeks, and 
biweekly for four weeks (i.e., 6 total meetings), to provide cotinine and CO samples. 
Participants received prize draws during therapy meetings if their cotinine levels were 
less than either the most recent level, or level 2. Participants used the same prize urn 
specified in the MS+CM condition, but began with 5 draws, which escalated to a 
maximum of 10 draws for subsequent negative cotinine tests. Reset contingencies were 
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in-place for positive tests or missed sessions. The prize urn was similar to that 
described above for Phase 2a and participants had the opportunity to earn up to 45 
draws plus 5 bonus draws over the 8-week treatment period, with an average maximum 
dollar value of $133 in prizes. 
Measures 
 Demographics and Inclusion/Exclusion. Gender, age, marital status, 
education and annual income were collected at intake. To assess exclusion criteria, a 
brief screen of suicidality, psychosis, and substance use symptoms were used, adapted 
using scales from the Structured Clinical Interview for the DSM-IV-TR (First, Spitzer, 
Gibbon, & Williams, 2002).  
 Smoking History. At the time of the intake interview, participants were asked 
about age of first smoking, age of first daily smoking, current number of cigarettes 
typically smoked daily, past quit attempts, and periods of abstinence. The Fagerström 
questionnaire was a brief measure of physical dependence to nicotine (Fagerström, 
1978; Heatherton et al., 1991) and was used as a measure of nicotine dependence.  
Things I Have Seen and Heard (TSH). A modified version of the TSH (Richters 
& Martinez, 1990) was used to assess exposure to community violence. The TSH 
includes 20 items that assessed exposure to neighborhood violence, specifically 
measuring witnessing or being victimized by violence in the community. Respondents 
self-reported their lifetime exposure to specific violent events on a 5-point scale ranging 
from “never” to “always.” The TSH demonstrates good psychometric properties, 
including internal consistency (Cronbach’s alpha = .76-.80; Richters & Martinez). The 
TSH was administered at intake. 
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Revised Conflict Tactics Scale—Short Form (CTS2S). The CTS2S is a brief 
form of the Revised Conflict Tactics Scale (Straus & Douglas, 2004). It includes 20 
items that measure exposure to interpersonal violence among intimate partners, 
assessing psychological and physical attacks experienced and perpetrated in the past 
year. The CTS2S demonstrates good internal consistency, test-retest reliability, and 
validity (Straus, Hamby, Boney-McCoy, & Sugarman, 1996). The CTS2S was 
administered at intake. 
 Beck Depression Inventory, Second Edition (BDI-II). The Beck Depression 
Inventory, Second Edition (BDI-II) is a 21-item self-report measure of past 14-day 
depression symptoms (Beck, Steer, & Garbin, 1988). Scores range from 0-63, with 
scores of 0-13 categorized as Minimal Depression, scores of 14-19 categorized as Mild 
Depression, scores of 20-28 categorized as Moderate Depression, and scores of 29-63 
categorized as Severe Depression. The BDI-II is a widely used, valid, and reliable 
measure of recent depression symptoms. The BDI-II was administered at intake.  
Quality of Life Inventory (QOL). The QOL assesses satisfaction in 17 life 
areas, including work, health, recreation, and goals (Frisch, 1994). This measure was 
used to assess life satisfaction. The QOL has test-retest coefficients ranging from .80-
.91 and correlates with other measures of well-being (Frisch et al., 2005). The QOL was 
administered at intake.  
Interpersonal Support Evaluation List (ISEL). The ISEL (Cohen & Hoberman, 
1983) is a 40-item scale that provides an index of overall perceived social support. The 
ISEL assesses appraisals, belongingness, available help, and self-esteem support. 
Response options range from definitely false (1) to definitely true (4), with high scores 
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indicating greater overall social support. The ISEL total score demonstrates good 
reliability in a variety of samples (Cronbach’s alpha = .88-.90; Cohen & Hoberman, 
1983). The ISEL was administered at intake. 
Cotinine. Cotinine is nicotine metabolite and a sensitive measure of smoking 
that was assessed by urinalysis using the Accutest NicAlert test-strip system (JANT 
Pharmacal Corporation). Through this test-strip system, cotinine was reported semi-
quantitatively, with ordinal scores of 0 through 6 being assigned based on cotinine 
concentrations (ng/mL). Level 0 indicates 1-10 ng/mL; level 1 indicates 11-30 ng/mL; 
level 2 indicates 31-100 ng/mL; level 3 indicates 101-200 ng/mL; level 4 indicates 201-
500 ng/mL; level 5 indicates 501-1000 ng/mL; level 6 indicates > 1000 ng/mL. Cotinine 
levels less than or equivalent to 100 ng/mL, or < level 2, were considered negative for 
cigarette smoking (Benowitz, Hukkanen, & Jacob, 2009).  
Due to the variance within each ordinally assigned level and the subsequent 
inability to analyze precise cotinine concentrations, a change score (X-Y) was used to 
assess whether cotinine level was reduced from intake (X) to post-treatment (Y). This 
was done to better detect change in smoking abstinence. Use of change scores as 
dependent variables is effectively used in regression analyses (Allison, 1990). Change 
scores may be limited by the fact that they are associated with both baseline and time-
point (post-Phase 1 and 2) scores. However, use of change scores in this study 
preserves power of analyses relative to alternative methods of change measurement 
(e.g., predicting raw time-point scores while additionally controlling for baseline scores) 
by reducing the number of variables analyzed. Though cotinine was assessed at 
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various time points, cotinine levels assessed following the first and second treatment 
phases were used for the current analyses. 
Timeline Follow-back – Cigarette (TLFB-C). The TLFB-C is a self-report, 
calendar-based measure of the quantity and frequency of cigarette smoking (Sobell et 
al., 1979). Average number of cigarettes smoked in the past month (30 days) was used 
to assess cigarette use. This particular measure of cigarette use with the TLFB-C is 
valid and reliable (Brown et al., 1998; Robinson, Sobell, Sobell, & Leo, 2012). To better 
understand change in cigarette use from pre to post-treatment, a change score (X-Y) 
was assessed from intake (X) to post-Phase 1 (Y) and 2 (Z) (Allison, 1990). Though the 
TLFB-C will be administered at various time points, TLFB-C scores assessed following 
completion of the first and second treatment phases were used for the current analyses.  
Longest Duration of Continuous Abstinence (LDA). Duration of continuous 
abstinence from smoking was measured in days, and is defined as the number of the 
longest string of consecutive days of smoking abstinence (Ledgerwood, Arfken, Petry, & 
Alessi, 2014). LDA was constructed using the TLFB-C in conjunction with (i.e., 
confirmed by) reported cotinine levels, and used data from intake to the conclusion of 
treatment (post-Phase 2). LDA is a robust predictor of future abstinence (Ferguson et 
al., 2003; Petry, Alessi, & Ledgerwood, 2012). 
Minnesota Nicotine Withdrawal Scale (MNWS). The MNWS is a 15-item self-
report of nicotine withdrawal symptoms such as anxiety, hunger, and irritability 
(Cappelleri et al., 2005; Hughes & Hatsukami, 1986). Each symptom is rated on a 5-
point scale ranging from “no” to “severe” withdrawal symptoms. To better understand 
change in withdrawal from pre to post-treatment, a change score (X-Y) was assessed 
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from intake (X) to post-Phase 1 (Y) and 2 (Z) (Allison, 1990). Though the MNWS was 
administered at various time points, MNWS scores assessed following the first and 
second treatment phases were used for the current analyses. 
 Questionnaire of Smoking Urges (QSU-Brief). The brief form of the QSU is a 
10-item self-report measure that assesses craving to smoke, including anticipated 
positive effects of smoking, and intention to smoke (Davies, Willner, & Morgan, 2000; 
Willner, Hardman, & Eaton, 1995; Tiffany & Drobes, 1991). To better understand 
change in urges from pre to post-treatment, a change score (X-Y) was assessed from 
intake (X) to post-Phase 1 (Y) and 2 (Z) (Allison, 1990). Though the QSU was 
administered at various time points, QSU scores assessed following the first and 
second treatment phases was used for the current analyses.  
Reasons for Quitting (RFQ). The RFQ is a 20-item self-report measure of 
motivation to quit smoking (Curry et al., 1991). This measure includes four scales, with 
two reflecting intrinsic motivation (health concerns and desire for self-control), and two 
reflecting extrinsic motivation (immediate reinforcement and social influence). The 
present study uses the RFQ total score in order to understand overall motivation to quit 
smoking. This scale has been validated in studies of smokers (Curry, et al., 1991). To 
better understand change in motivation to quit smoking from pre to post-treatment, a 
change score (X-Y) was assessed from intake (X) to post-Phase 1 (Y) and 2 (Z) 
(Allison, 1990). Though the RFQ was administered at various time points, RFQ scores 
assessed following completion of the first and second treatment phases were used for 
the current analyses. 
Analysis of Aims 
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Four hypotheses were tested using hierarchical multiple regressions. (1) The 
relationship between increased violence exposure (community violence, intimate 
partner violence) and smoking cessation outcomes (change in cotinine scores, cigarette 
use, withdrawal, urges, motivations for quitting smoking, and LDA for the total treatment 
period) was tested while controlling for differences explained by sociodemographic and 
initial treatment condition variables (age, gender, education, nicotine dependence, initial 
treatment condition assignment). This regression included community violence and 
intimate partner violence scores as predictor variables in the first hierarchical regression 
block, and sociodemographic and treatment variables in the second regression block. 
Primary study variables were entered in the first blocks to gain a better understanding of 
both the model fit of the primary study variables, and the model fit of the primary 
variables while secondarily controlling for sociodemographic variables and initial 
treatment condition (e.g., Newman & Thompson, 2003). Outcome variables measured 
at the completion of Phase 1 (Post-Phase 1 change in cotinine, cigarette use, 
withdrawal, urges, motivations for quitting smoking) and outcome variables measured at 
the completion of Phase 2 (Post-Phase 2 change in cotinine, cigarette use, withdrawal, 
urges, motivations for quitting smoking, and LDA) were assessed in separate regression 
sets.  
(2) The relationship between higher depressive symptoms scores and lower life 
satisfaction scores and smoking cessation outcomes (change in cotinine scores, 
cigarette use, withdrawal, urges, motivations for quitting smoking, and LDA for the total 
treatment period) was tested while controlling for differences explained by 
sociodemographic and initial treatment condition variables (age, gender, education, 
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nicotine dependence, initial treatment condition assignment). This regression included 
depressive symptoms and life satisfaction scores as predictor variables in the first 
hierarchical regression block, and sociodemographic and treatment variables in the 
second regression block (Newman & Thompson, 2003). Outcome variables measured 
at the completion of Phase 1 (Post-Phase 1 change in cotinine, cigarette use, 
withdrawal, urges, motivations for quitting smoking) and outcome variables measured at 
the completion of Phase 2 (Post-Phase 2 change in cotinine, cigarette use, withdrawal, 
urges, motivations for quitting smoking, and LDA) were assessed in separate regression 
sets. 
(3) The relationship between social support and smoking cessation outcomes 
(change in cotinine scores, cigarette use, withdrawal, urges, motivations for quitting 
smoking, and LDA for the total treatment period) and (4) the moderation of social 
support on the relationships between violence exposure and smoking, depressive 
symptoms and life satisfaction and smoking was tested while controlling for differences 
explained by sociodemographic and initial treatment condition variables (age, gender, 
education, nicotine dependence, initial treatment condition assignment). Regressions 
included social support and primary predictor variables (community violence and 
intimate partner violence exposure; depressive symptoms and life satisfaction scores) in 
the first blocks, and sociodemographic and treatment variables in the second blocks 
(Newman & Thompson, 2003). Third blocks included two-way interaction terms between 
social support and predictor variables (social support by exposure to community 
violence, and social support by intimate partner violence; social support by depressive 
symptoms scores, and social support by life satisfaction scores). Regressions were run 
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separately for each primary predictor variable to reduce collinearity and increase the 
power of analyses. Outcome variables measured at the completion of Phase 1 (Post-
Phase 1 change in cotinine, cigarette use, withdrawal, urges, motivations for quitting 
smoking) and outcome variables measured at the completion of Phase 2 (Post-Phase 2 
change in cotinine, cigarette use, withdrawal, urges, motivations for quitting smoking, 
and LDA) were assessed in separate regression sets.  
Analyses did not involve correction procedures for the study’s 22 multiple 
regressions and 24 moderation regressions. This decision was made because the 
consequent reduction in Type I statistical error (i.e., false discoveries) would 
subsequently increase the probability of Type II statistical error (i.e., false rejections), 
particularly with the modest sample size of the current study (Gelman, Hill, & Yajima, 
2012).  
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CHAPTER 3: RESULTS 
Preliminary Analyses 
Statistical Package for the Social Sciences (SPSS) Version 22 was used for all 
analyses. Adequate power existed for all analyses given these statistical tests and the 
present study’s sample size. This determination was based on literature which reports a 
standard of five observations needed per independent variable in multiple linear 
regression to maintain adequate power (Bartlett, Kotrlik, & Higgins, 2001; Hair, 
Anderson, Tatham, & Black, 1995). In addition, a power analysis was conducted using 
Gpower 3.1.9.2 statistical analysis software (Faul, Erdfelder, Lang, & Buchner, 2007). 
This power analysis of the current study parameters reported a power statistic of .81 at 
a .05 significance criterion, indicating adequate statistical power for the current analyses 
(Cohen, 1998; Ellis, 2010).  
Data were screened for accuracy of input, univariate and multivariate outliers, 
and amount and distribution of missing data (see Table 1 for full descriptive statistics). 
No univariate or multivariate outliers were detected. Six participants failed to complete 
the intended 12-week treatment. Missing data for these 6 participants were identified as 
data not-missing-at-random. Missing data for these participants were imputed by 
method of last observation carried forward (LOCF). LOCF is a frequently used, 
conservative (i.e., underestimates, rather than falsely overestimates, true treatment 
effects) method of data imputation in longitudinal studies (Gelman & Hill, 2006), 
particularly when data are missing not-at-random (Higgins & Green, 2011). LOCF 
additionally avoids distorting both the distribution of data, and multivariate relationships, 
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as commonly occurs when missing data are replaced with the mean of observed values 
(i.e., mean imputation; Gelman & Hill).  
Normality and linearity among variables were examined using skew and kurtosis 
statistics, histograms of standardized residuals, and P-Plots of regression standardized 
residuals. Calculations of skew and kurtosis identified skew among the outcome 
variables of Post-Phase 1 and Post-Phase 2 cotinine change scores, and LDA (using a 
skew and kurtosis cut-off level of +1.96). Variables were transformed for normality using 
square root and log transformations; however, variables remained above the cut-off 
level indicating skew and kurtosis. Skew of these variables was interpreted as related to 
the smoking severity of the current sample, particularly with use of the ordinal-level, 
range-restricted variable of cotinine. Residual plots of standardized residuals appeared 
linear and homogenous, and thus indicated appropriate fit of study variables to 
parametric analyses (Stevens, 2009). Research further indicates that multiple 
regression analysis is robust to assumptions of normality (Frost, 2014; Gelman & Hill, 
2007; van Belle, 2008). Variables were additionally screened for multicollinearity and 
singularity by examination of bivariate correlations, variance inflation factors (VIF), and 
tolerance statistics. There was no evidence of multicollinearity or singularity. Bivariate 
correlations were calculated for all study variables (see Table 2).  
Sociodemographic Variables. Descriptive statistics for all study variables are 
presented in Table 1. Participants (N = 40) were 25-63 years old (M = 46.95, SD = 
9.81). Participants included more men (N = 25; 62.5%) than women (N = 15; 37.5%). 
The majority of participants were African-American (N = 38; 95%), with the remainder 
identifying as Caucasian (n = 1; 2.5%) and Hispanic (N = 1; 2.5%). Sixty-eight percent 
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of the sample (N = 27) completed at least 12 years of education. The mean Fagerström 
Test for Nicotine Dependence score was 5.5 (SD = 1.97) indicating an overall Moderate 
level of nicotine dependence. Fifty-five percent of the sample (N = 22) was initially 
randomized to the standard of care treatment condition; 45% (N = 18) were initially 
randomized to the contingency management treatment condition.  
Predictor Variables. Participants reported a mean BDI-II depression score of 
15.1 (SD = 12.41) indicating an overall Mild level of depression. Measures of community 
violence (The Things I Have Seen and Heard), intimate partner violence (Revised 
Conflict Tactics Scale - Short Form), social support (Interpersonal Support Evaluation 
List), and life satisfaction (Quality of Life Inventory) do not indicate clinical significance 
thresholds and are described below.  
Total possible TSH community violence scores range from 0-54, with greater 
scores indicating more exposure to community violence. Participants reported a mean 
community violence score of 28.25 (SD = 13.11). All participants reported exposure to 
at least one lifetime community violence event. Specific violence items endorsed are 
presented in Table 11.  
Total possible CTS2S intimate partner violence scores range from 0-120, with 
greater scores indicating more exposure to intimate partner violence. Participants 
reported a mean partner violence score of 15.60 (SD = 14.30). Sixty percent of 
participants reported at least one partner violence victimization event in the past year. 
Specific violence victimization items endorsed are presented in Table 12. Sixty-eight 
percent of participants reported at least one partner violence perpetration event in the 
past year. Specific violence items endorsed are presented in Table 13. 
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Total possible ISEL social support scores range from 0-160, with higher scores 
indicating greater perceived social support. Total social support scores reported in this 
sample ranged from 61 to 147. Participants reported a mean total social support score 
of 121.20 (SD = 22.00). ISEL social support subscales include Appraisal (perceived 
availability of others to trust and confide in), Tangible support (perceived availability of 
instrumental help), Self-Esteem support (perceived positive comparisons in 
interpersonal relationships), and Belongingness support (perceived sense of social 
belongingness). Possible subscale scores range from 0-40. Participants reported a 
mean Appraisal subscale score of 30.93 (SD = 6.16). The mean Tangible support 
subscale score was 29.73 (SD = 6.10). The mean Self-Esteem support subscale score 
was 29.58 (SD = 5.35). The mean Belongingness support subscale score was 30.98 
(SD = 6.44). All four ISEL social support subscale scores were comparable, with means 
ranging from 29.58 to 30.98. The ISEL total perceived social support score was used in 
the current analyses.  
Total possible life satisfaction scores on the Quality of Life Inventory range from -
51 to 51 (with individual items endorsed on a scale from -3, or very dissatisfied, to 3, 
very satisfied). Higher scores indicate greater life satisfaction. Total life satisfaction 
scores in the current sample ranged from -33 to 51. Participants reported a mean total 
life satisfaction score of 13.75 (SD = 21.61). Mean life satisfaction scores reported in 
each of the 17 areas of functioning are presented in Table 14. As seen in Table 14, 
participants reported the lowest life satisfaction scores in the following three areas: 
Standard of Living (income, possessions such as cars or furniture, and expectations for 
having financial needs met), Work (pay, surroundings, security, relationships with co-
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workers, and availability of needed equipment and supervision), and Health (being 
physically fit and free from sickness, pain, or disability). The highest life satisfaction 
scores were reported in the following three areas: Relationships with Children (getting 
along with, helping, teaching, and caring for child/children), Friendships (number and 
quality of close friends with mutual companionship, acceptance, trust, and support), and 
Social Service (helping, encouraging, and promoting the welfare of others such as 
through church, clubs, or volunteer groups). 
Outcome Variables. Change scores (X-Y) were assessed for all outcome 
variables with the exception of longest duration of abstinence (LDA). As previously 
noted, cotinine scores are reported semi-quantitatively, with ordinal scores of 0-6 being 
assigned based on cotinine concentrations. Of note, there is unequal variance within 
each ordinally assigned level (e.g., a score of 0 indicates cotinine levels of 1-10 ng/mL, 
while a score of 6 indicates cotinine levels of >1000 ng/mL). The mean baseline cotinine 
score was 5.63 (SD = .93) indicating a high level of cigarette use at baseline. The mean 
change in cotinine scores from baseline to Time 1 was .50 (SD = .18), and mean 
change in cotinine scores from baseline to Time 2 was .55 (SD = .20). Higher change 
scores indicate decreased cotinine levels from baseline to time point.  
The mean past-month number of cigarettes smoked at baseline was 13.97 (SD = 
1.09). Mean change in cigarette use from baseline to Time 1 was 8.29 (SD = .91), and 
mean change in cigarette use from baseline to Time 2 was 9.12 (SD = 1.12). Higher 
change scores indicate decreased cigarette use from baseline to time point. Participants 
reported a mean LDA (longest string of consecutive days of smoking abstinence) score 
of 10.43 (SD = 16.56) throughout the duration of treatment. 
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Total Minnesota Nicotine Withdrawal Scale (MNWS) scores range from 0-60 with 
higher scores indicating greater withdrawal. Mean change in MNWS withdrawal scores 
at baseline was 20.33 (SD = 15.88). Mean change in withdrawal scores from baseline to 
Time 1 was 4.0 (SD = 1.92), and mean change in withdrawal from baseline to Time 2 
was 3.98 (SD = 2.06). Higher change scores indicate decreased withdrawal symptoms 
scores from baseline to time point. 
Total Questionnaire of Smoking Urges (QSU) scores range from 0-70 with higher 
scores indicating more smoking urges. Mean QSU smoking urges scores at baseline 
was 45.95 (SD = 15.37). Mean change in smoking urges from baseline to Time 1 was 
21.33 (SD = 2.66), and mean change in smoking urges from baseline to Time 2 was 
22.35 (SD = 2.66). Higher change scores indicate decreased smoking urges scores 
from baseline to time point. 
Total Reasons for Quitting Smoking (RFQ) scores range from 0-80 with higher 
scores indicating greater motivations to quit smoking. The mean RFQ quitting 
motivations score was 42.90 (SD = 15.72). Mean change in quitting smoking 
motivations from baseline to Time 1 was -1.65 (SD = 1.92), and mean change in quitting 
smoking motivations from baseline to Time 2 was .43 (SD = 2.64). Lower change scores 
indicate increased motivations to quit smoking from baseline to time point. 
Differences by Sociodemographic Variables. Differences on exposure to 
community violence, exposure to interpersonal violence, depression scores, life 
satisfaction, and perceived social support, as well as differences on the outcome 
variables of cotinine, LDA, cigarette use, withdrawal, smoking urges, and motivations for 
quitting smoking, were examined by socio-demographic variables (age, gender, 
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ethnicity, education, and nicotine dependence), and initial treatment condition. These 
tests were conducted to determine if there were significant group differences based on 
baseline demographic and study characteristics. Comparisons were conducted using 
analysis of variance (ANOVA). There were no significant differences in the predictor or 
outcome variables based on age, ethnicity, education, nicotine dependence, or initial 
treatment condition. Results showed a significant difference in community violence 
exposure by gender (F(1, 38) = 4.53, p < .05), with men reporting greater community 
violence exposure.  
Primary Analyses 
Effect of Violence, Depressive Symptoms, and Life Satisfaction on 
Smoking Cessation. Hierarchical multiple regressions were used to assess the unique 
effect of each predictor variable on each outcome variable while controlling for 
differences explained by sociodemographic variables and initial treatment condition. 
Variables were entered in two hierarchical blocks. For all regressions, the first block 
contained primary predictor variables (community violence, and intimate partner 
violence; depressive symptoms, and life satisfaction). In the second blocks, 
sociodemographic and initial treatment condition variables (age, gender, education, 
initial treatment condition assignment, and Fagerström nicotine dependence scores) 
were entered. As 95% of the sample was African-American, ethnicity was not 
associated with any predictor or outcome variables; thus, the sociodemographic 
variable of ethnicity was excluded from all future regression analyses. Primary study 
variables were entered in the first block to gain a better understanding of both the model 
fit of the primary study variables, and the model fit of the primary variables while 
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secondarily controlling for sociodemographic variables and initial treatment condition 
(e.g., Newman & Thompson, 2003).  
Regressions were run separately for violence variables (community violence, and 
intimate partner violence), and mood/protective variables (depressive symptoms, and 
life satisfaction). Five regressions were run with community violence and intimate 
partner violence predicting each post-Phase 1 (initial smoking response) outcome 
variable (change in cotinine, cigarette use, withdrawal, urges, and motivations for 
quitting). Six regressions were run with community violence and intimate partner 
violence predicting each post-Phase 2 (total cessation treatment response) outcome 
variable (change in cotinine, cigarette use, withdrawal, urges, motivations for quitting, 
and LDA). Five regressions were run with depressive symptoms and life satisfaction 
predicting each post-Phase 1 outcome variable separately. Finally, six regressions were 
run with depressive symptoms and life satisfaction predicting each post-Phase 2 
outcome variable separately. In total, 22 regressions were run. 
Initial smoking cessation response was assessed by analyzing intake predictor 
variables and post-Phase 1 outcome variables, excluding the outcome of longest 
duration of abstinence (LDA), which measured continuous abstinence throughout the 
total 12-week treatment period (Phase 1 and Phase 2). Total cessation treatment 
response was assessed by analyzing intake predictor variables and post-Phase 2 
outcome variables. For both post-Phase 1 and post-Phase 2 outcome variables, change 
scores (X-Y) were assessed from intake (X) to post-Phase 1 (Y) and 2 (Z) for the 
variables of cotinine, withdrawal, urges, and motivations for quitting smoking.  
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Treatment condition in Phase 1 was assessed as a predictor variable in both 
post-Phase 1 and post-Phase-2 regressions. Though it would be ideal to analyze Phase 
2 treatment condition in the post-Phase 2 analysis, Phase 2 treatment condition was 
confounded by the role of initial treatment response in Phase 2 treatment assignments; 
thus, initial (Phase 1) treatment condition alone was controlled for in analyses of both 
post-Phase 1 and post-Phase 2 outcomes. 
Effect of Violence on Initial Smoking Cessation. Results are presented in Table 3. 
There were no significant effects of predictors on Post-Phase 1 (initial) change in 
cotinine, withdrawal, or smoking urges (all ps > .05). There were significant effects of 
predictors on initial change in motivations to quit smoking and cigarette use (described 
below). 
There was a significant effect of Block 1 (community violence and intimate 
partner violence exposure) on change in cigarette use (F(2, 37) = 6.07, p < .05). Block 1 
of this model explained 13.8% (R2) of the total variance in cigarette use. In Block 1, 
intimate partner violence exposure significantly predicted initial cigarette use (β = -.37, p 
< .05), with greater intimate partner violence exposure being related to increased 
cigarette use relative to intake. Block 2, which contained sociodemographic and initial 
treatment variables, was also significant (F(2, 37) = 2.92, p < .05). Block 2 did not 
significantly explain increased variance in cigarette use from Block 1 (∆F = 2.11, p = 
.09). In Block 2, partner violence remained significant (β = -.10, p < .05) and was related 
to increased cigarette use. Gender was also significant (β = -.33, p = .05), with male 
gender being related to reduced cigarette use. 
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There was a significant effect of Block 1 (community violence and intimate 
partner violence exposure) on initial change in motivations for quitting smoking (F(2, 37) 
= 3.34, p < .05). Block 1 of this model explained 15.3% (R2) of the total variance in 
motivations for quitting smoking. In Block 1, community violence exposure significantly 
predicted initial motivations for quitting smoking (β = 2.49, p < .05), with greater 
community violence exposure being related to decreased motivations to quit smoking 
relative to intake. Block 2, which contained sociodemographic and initial treatment 
variables, was not significant (p > .05).  
Effect of Violence on Total Smoking Cessation. Results are presented in Table 4. 
There were no significant effects of predictors on Post-Phase 2 (total treatment) change 
in cotinine, cigarette use, withdrawal, urges, motivations for quitting smoking, or LDA (all 
ps > .05).  
Effect of Depressive Symptoms and Life Quality on Initial Smoking Cessation. 
Results are presented in Table 5. There were no significant effects of predictors on 
initial change in cotinine, urges, or motivations for quitting smoking (all ps > .05). There 
were significant effects of predictors on initial change in withdrawal and cigarette use 
(described below). 
There was a significant effect of Block 2 (sociodemographic and initial treatment 
condition variables) on initial change in cigarette use (F(2, 37) = 2.58, p < .05). Block 2 
of this model explained 36% (R2) of the variance in initial treatment cigarette use, which 
represented a significant increase in variance explained from Block 1 of the model (∆F = 
3.50, p < .05). In Block 2 of this model, gender significantly predicted initial cigarette use 
(β = -.33, p < .05), with male gender being related to reduced cigarette use relative to 
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intake. Block 1 (depressive symptoms scores and life quality) was not significant (p > 
.05). 
There was a significant effect of depressive symptoms and life satisfaction 
scores (Block 1) on initial change in withdrawal symptoms (F(2, 37) = 3.27, p < .05). 
Block 1 (depressive symptoms and life satisfaction) of this model explained 15% (R2) of 
the total variance in withdrawal from smoking. In Block 1, depressive symptoms scores 
significantly predicted smoking withdrawal (β = 2.33, p < .05), with greater depressive 
symptoms being related to reduced experience of initial withdrawal symptoms. Block 2, 
which contained sociodemographic and initial treatment variables, was not significant (p 
> .05). 
Effect of Depressive Symptoms and Life Quality on Total Smoking Cessation. 
Results are presented in Table 6. There were no significant effects of predictors on total 
treatment change in cotinine, urges, motivations for quitting smoking, or LDA (all ps > 
.05). There was a significant effect of predictors on total treatment change in withdrawal 
(described below). 
There was a significant effect of depressive symptoms and life satisfaction 
scores (Block 1) on total treatment change in withdrawal (F(2, 37) = 3.62, p < .05). 
Block 1 of this model explained 16.4% (R2) of the total variance in total treatment 
smoking withdrawal. In Block 1, depressive symptoms scores significantly predicted 
smoking withdrawal (β = 2.64, p < .05), with greater depressive symptoms being related 
to reduced post-Phase 2 smoking withdrawal relative to intake. Block 2, which 
contained sociodemographic and initial treatment variables, was not significant (p > 
.05). 
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Moderating Effect of Social Support. Hierarchical regressions were used to 
assess the moderating effects of social support, as measured by the ISEL. This analysis 
allowed for evaluation of both the independent and interactive effects of social support 
on all outcome variables while controlling for differences explained by 
sociodemographic and initial treatment variables (Aiken & West, 1991).  
 Variables were entered into the regression equation by blocks. In the first block, 
social support and primary predictor variables (community violence and intimate partner 
violence; depressive symptoms and life quality) were entered. In the second block, 
sociodemographic and initial treatment variables (age, gender, education, initial 
treatment condition, and nicotine dependence scores) were added. The third step 
added two-way interaction terms between social support and predictor variables (social 
support by exposure to community violence, and social support by intimate partner 
violence; social support by depressive symptoms, and social support by life 
satisfaction). These regressions were run separately for each primary predictor variable. 
This was done to reduce collinearity and increase power of analyses. Regressions were 
run separately for each outcome variable. In total, 24 moderation regressions were run. 
To determine if the interactions entered in the third block significantly added to 
the variance in the given outcome variable, significant change in the F statistic was 
examined (West & Aiken, 1997, 1991). If the third model yielded significant change, 
social support and the given predictor significantly interacted to predict the outcome 
variable. Squared semi-partial correlations were also examined to determine the unique 
effects of each predictor and interaction.  
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Moderating Effect of Social Support on Violence in Predicting Initial Smoking 
Cessation. There were no independent or moderated effects on initial change in 
cotinine, withdrawal, urges, or motivations for quitting smoking (all ps > .05). There were 
significant model effects for initial change in cigarette use only (described below and 
presented in Table 7). Results showed no significant moderation effects for any 
outcome variables.   
There was a significant effect of the model containing community violence, social 
support, and sociodemographic and treatment variables, on initial treatment change in 
cigarette use (Table 7). Block 1 (community violence and social support) was not 
significant (p > .05). There was a significant effect of Block 2 (sociodemographic and 
initial treatment variables added) on initial treatment cigarette use (F(7, 32) = 2.40, p < 
.05). Block 2 of this model explained 34% (R2) of variance in initial change in cigarette 
use, and significantly increased variance explained from Block 1 (∆F = 3.35, p < .05). In 
Block 2 of this model, gender significantly predicted initial change in cigarette use (β = -
.34, p < .05), with male gender being related to decreased cigarette use (measured 
relative to intake). Block 3 (community violence by social support interaction term 
added) was significant (F(8, 31) = 2.23, p < .05). Block 3 of this model explained 37% 
(R2) of variance in initial change in cigarette use, but did not significantly increase 
variance explained from Block 1 (∆F = 1.03, p > .05). In Block 3 of this model, gender 
alone significantly predicted initial change in cigarette use (β = -.37, p < .05), with male 
gender being related to decreased cigarette use from intake.  
There was a significant effect of the model containing intimate partner violence, 
social support, and sociodemographic and treatment variables, on initial change in 
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cigarette use (Table 7). Block 1 (intimate partner violence and social support) was not 
significant (p > .05). Block 2 of this model added sociodemographic and initial treatment 
variables, and showed a significant effect on initial change in cigarette use (F(7, 32) = 
2.43, p < .05). Block 2 of this model explained 35% (R2) of variance in total treatment 
cigarette use, but did not significantly increase variance explained from Block 1 (∆F = 
2.03, p > .05). In Block 2 of this model, gender significantly predicted initial change in 
cigarette use (β = -.31, p <.05), with male gender being related to decreased cigarette 
use relative to intake. Block 3 (intimate partner violence by social support interaction 
term added) was significant (F(8, 31) = 2.32, p < .05), and explained 37% (R2) of 
variance in total treatment cigarette use, but did not significantly increase variance 
explained from Block 2 (∆F = 1.36, p > .05). In Block 3 of this model, gender alone 
significantly predicted initial change in cigarette use (β = -.32, p < .05), with male gender 
being related to decreased cigarette use from intake. 
Moderating Effect of Social Support on Violence in Predicting Total Smoking 
Cessation. There were no independent or moderated effects on total treatment change 
in cotinine, cigarette use, withdrawal, urges, motivations for quitting smoking, or LDA (all 
ps > .05). Results showed no significant moderation effects for any outcome variables.   
Moderating Effect of Social Support on Depressive Symptoms and Life Quality in 
Predicting Initial Smoking Cessation. There were no independent or moderated effects 
on initial change in cotinine, urges, or motivations for quitting smoking (all ps > .05). 
There were significant model effects for initial change in withdrawal and cigarette use 
(described below and presented in Tables 8-9). Results showed no significant 
moderation effects for any outcome variables.  
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There was a significant effect of the model containing depressive symptoms, 
social support, and sociodemographic and treatment variables, on initial change in 
withdrawal symptoms (Table 8). Block 1 (depressive symptoms and social support) 
significantly predicted initial change in withdrawal (F(2, 37) = 3.28, p < .05), and 
explained 15% (R2) of the variance in initial smoking withdrawal. In Block 1 of this 
model, depressive symptoms scores significantly predicted initial change in withdrawal 
symptoms (β = 2.10, p < .05), with higher depression scores being related to reduced 
withdrawal relative to intake. Block 2 of this model added sociodemographic and initial 
treatment variables, and was not significant (p > .05); however, depression scores 
remained a significant predictor in this block (β = 2.14, p < .05). Block 3 of this model 
added the interaction of social support and depressive symptoms, and was not 
significant (p > .05).  
There was a significant effect of the model containing depressive symptoms, 
social support, and sociodemographic and treatment variables, on initial change in 
cigarette use (Table 9). Block 1 (depressive symptoms and social support) was not 
significant. There was a significant effect of Block 2 (sociodemographic and initial 
treatment variables added) on initial treatment change in cigarette use (F(7, 32) = 2.57, 
p < .05). Block 2 of this model explained 36% (R2) of variance in initial cigarette use, 
and significantly increased variance explained from Block 1 (∆F = 3.57, p < .05). In 
Block 2 of this model, gender (β = -.33, p < .05) and education (β = -.33, p < .05) 
significantly predicted initial cigarette use, with male gender and higher level of 
education being related to decreased cigarette use relative to intake. There was a 
significant effect of Block 3 on initial change in cigarette use (F(8, 31) = 2.31, p < .05). 
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Block 3 of this model explained 37% (R2) of variance in initial change in cigarette use, 
but did not significantly increase variance explained from Block 2 (∆F = .64, p > .05). In 
Block 3, gender (β = -.38, p < .05) and education (β = -.34, p < .05) significantly 
predicted initial change in cigarette use. Male gender and higher education level related 
to decreased cigarette use relative to intake. 
There was a significant effect of the model containing life satisfaction, social 
support, and sociodemographic and treatment variables, on initial change in cigarette 
use (Table 9). Block 1 (life satisfaction and social support) was not significant (p > .05). 
Block 2 of this model added sociodemographic and initial treatment variables. There 
was a significant effect of Block 2 on initial change in cigarette use (F(7, 32) = 2.57, p < 
.05). Block 2 of this model explained 36% (R2) of the variance in initial change in 
cigarette use and significantly increased variance explained (∆F = 3.48, p < .01). In 
Block 2 of this model, gender (β = -.34, p < .05) and education (β = -.33, p < .05) 
significantly predicted initial cigarette use, with male gender and higher level of 
education being related to decreased initial cigarette use relative to intake. Block 3 
added the interaction term between social support and depressive symptoms. There 
was a significant effect of Block 3 on total treatment cigarette use (F(8, 31) = 2.36, p < 
.05). Block 3 of this model explained 38% (R2) of variance in initial cigarette use, but did 
not significantly increase explained variance (∆F = .90, p > .05). In Block 3, gender (β = 
-.38, p < .05) and education (β = -.35, p < .05) remained significant predictors, with male 
gender and higher level of education being related to decreased cigarette use relative to 
intake. 
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Moderating Effect of Social Support on Depressive Symptoms and Life Quality in 
Predicting Total Smoking Cessation. There were no independent or moderated effects 
on total treatment change in cotinine, cigarette smoking, urges, motivations for quitting 
smoking, or LDA (all ps > .05). There were significant model effects for total treatment 
change in withdrawal only (described below and presented in Table 10). Results 
showed no significant moderation effects for any outcome variables.  
There was a significant effect of the model containing depressive symptoms, 
social support, and sociodemographic and treatment variables, on total treatment 
change in withdrawal symptoms (Table 10). Block 1 (depressive symptoms and social 
support) significantly predicted initial change in withdrawal (F(2, 37) = 3.32, p < .05), 
and explained 15.2% (R2) of variance in total smoking withdrawal. In Block 1 of this 
model, depressive symptoms scores significantly predicted total treatment change in 
withdrawal symptoms (β = .34, p < .05), with greater depression being related to 
reduced post-treatment withdrawal relative to intake. Block 2 of this model added 
sociodemographic and initial treatment variables, and was not significant (p > .05). 
Block 3 of this model added the interaction of social support and depressive symptoms, 
and was not significant (p > .05).  
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CHAPTER 4: DISCUSSION 
 The purpose of this study was to investigate the impact of protective and risk 
factors on smoking cessation among PLWHA in smoking cessation treatment. 
Specifically, this study examined the roles of two prevalent components of violence 
among this population, community violence and intimate partner violence, as well as 
two variables related to well-being, depression and life satisfaction.  This study also 
assessed the influence of the protective factor of social support on smoking cessation, 
including moderating effects of social support on violence and well-being variables in 
predicting smoking cessation outcomes. In addition to primary predictor variables, this 
study accounted for sociodemographic factors that are often associated with smoking 
cessation treatment outcomes. These factors included age, gender, education, baseline 
nicotine dependence scores, and initial treatment condition assignment in the larger 
clinical trial. 
 Outcome variables were a range of smoking indicators, including withdrawal 
symptoms, urges to smoke, motivations for quitting smoking, cotinine scores, self-
reported cigarette use, and longest duration of continuous abstinence (longest 
consecutive number of days not smoking). The purpose of including this range of 
smoking cessation variables was exploratory. These particular smoking indicators were 
chosen because they are central to both the experience (withdrawal, urges, motivations 
for quitting) and the assessment (cotinine, cigarette use, LDA) of quitting smoking, 
particularly among clinically high-risk groups (Leventhal, Ameringer, Osborn, Zvolensky, 
and Langdon, 2013; Leventhal et al., 2013; Reid & Ledgerwood, 2015; Weinberger, 
McKee, & George, 2012; Ziedonis et al., 2008). 
48 
 
 
Significant Findings 
 This study found that increased community violence predicted reduced 
motivations for quitting smoking (relative to intake) after the first phase of treatment. 
Increased intimate partner violence was related to increased cigarette use (relative to 
intake) after the first phase of treatment. These findings suggested that discrete 
components of violence exposure are differentially associated with smoking outcomes, 
particularly in the beginning of smoking cessation treatment. Increased experience of 
community violence appears to be related to a proxy of cigarette use (i.e., motivations 
for quitting smoking), while interpersonal violence is related to actual increase in 
smoking behaviors (i.e., number of cigarettes smoked). It is possible that interpersonal 
violence is experienced as being localized to the relationship, and thus predicts a more 
acute coping need, achieved through smoking. This is in-line with cross-cultural 
research showing that domestic violence is associated with tobacco use, particularly in 
areas where greater rates of violence are reported (Ackerson, Kawachi, Barbeau, & 
Subramanian, 2007).  
In contrast, community violence may be experienced more systemically, which 
could impact distal smoking behaviors. Systemic stress related to chronic experiences 
of community violence across multiple domains (e.g., neighborhood, home, 
school/work) may increase hopelessness, which may then mediate between community 
violence and motivations to quit smoking. Challenges related to these varying forms of 
violence are of particular importance as 100% of the current sample reported exposure 
to at least one lifetime community violence event, and 60% of the current sample 
reported experiencing partner violence victimization in the last year. Specific item 
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endorsements are illustrated in Table 11 (community violence) and Table 12 (intimate 
partner violence). 
Relationships between partner violence and increased cigarette use, and 
community violence and reduced quitting motivations, were found after the first phase of 
treatment only. Phase 1 (initial) treatment condition alone was controlled for in the 
present analyses, as Phase 2 treatment condition was confounded with the role of initial 
treatment response in Phase 2 treatment assignments. It is likely that because 
individuals are assigned to different treatment conditions in Phase 2 based on their 
response to treatment in Phase 1, Phase 2 treatment assignment was predictive of total 
treatment smoking cessation success.  
Participants who reported relatively greater depressive symptoms at baseline 
were more likely to demonstrate reductions in smoking withdrawal after both the first 
and second phases of treatment (relative to intake). This finding was congruent with 
previous literature showing that smokers with greater depression scores at baseline 
report significantly different withdrawal experience than smokers in the same treatment 
with lower depressive scores at baseline (Reid & Ledgerwood, 2015). Though it could 
be argued that withdrawal is experienced as a result of achieving abstinence from 
smoking, the previous study showed differences in withdrawal experience despite non-
differential levels of tobacco use throughout treatment (assessed through expired 
carbon monoxide).  
In order to further understand these differences in withdrawal experience as a 
function of depression scores, means and group differences for withdrawal were 
evaluated by depression score categorization. In the present study, greater depressive 
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symptoms scores at intake were associated with greater withdrawal sensitivity at intake 
(r = .76, p < .01), post-Phase 1 (r = .57, p < .01), and post-Phase 2 (r = .50, p < .01). To 
better evaluate differences in withdrawal experience in a clinically interpretable manner, 
depressive symptoms were dichotomized into low (scores < 13; n = 22) versus high 
scores (scores > 13; n = 18) based on BDI-II clinical significance cut-offs (with scores of 
0 to 13 representing Minimal depression, and 14 and above representing Moderate to 
Severe depression). Mean scores and group differences demonstrated that mean 
withdrawal scores were significantly higher among individuals reporting greater 
depressive symptoms, but that withdrawal decreased more for high-depression scorers 
(compared to low-depression scorers) between time points (see Figure 1).  
It is possible that smokers with higher depression scores demonstrated greater 
reductions in withdrawal throughout treatment by virtue of reporting significantly higher 
withdrawal scores at baseline; those with greater baseline depression scores reported 
almost four-fold higher withdrawal scores than those with low baseline depression 
scores. Additionally, unmeasured components of treatment, in particular, treatment of all 
participants with bupropion (commonly prescribed as an antidepressant), may have 
secondarily aided in reducing depressive symptoms. Buproprion treatment, though not 
prescribed in the present study for depression symptoms, may be associated with 
greater changes in withdrawal experience specifically for smokers with greater baseline 
depressive symptoms, and relatedly greater baseline withdrawal sensitivity.  
Increased initial sensitivity to withdrawal among individuals who report mood 
instability is potentially associated with decreased distress tolerance, or the ability to 
experience and manage negative internal states, as well as discomfort intolerance, or 
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the ability to withstand uncomfortable physical sensations (Ellis, Vanderling, & Beevers, 
2012; Schmidt & Lerew, 1998; Williams, Thompson, & Andrews, 2013). It is thus 
possible that individuals who report high depression scores have a more aversive initial 
experience of withdrawal from tobacco. PLWHA who have co-occurring tobacco use 
disorder and depression might then be increasingly vulnerable to greater dysphoria 
during initial withdrawal, particularly when withdrawal is experienced in combination with 
disease-related physical discomfort.  
The sociodemographic variable of male gender was related to greater reductions 
in cigarette use after the first phase of treatment (in models testing both mood and life 
satisfaction, and violence). This is congruent with men reporting more prevalence and 
severity of tobacco use, particularly among PLWHA (CDC, 2015; Mdodo et al., 2015; 
WHO, 2007), but demonstrating greater abstinence success across a variety of 
cessation treatments (Carlson et al., 2002; McKee et al., 2005; Scharf & Shiffman, 
2004; Wetter et al., 1999). One smoking cessation study in particular showed prominent 
gender differences in a treatment that incorporated bupropion and behavioral 
counseling (Collins et al., 2004). Collins and colleagues (2004) not only found that men 
were more likely to quit and remain abstinent after treatment and at follow-up, but also 
identified a gender interaction whereby women benefitted more from bupropion 
treatment if they were light smokers, and men benefitted more from bupropion if they 
were heavy smokers.  
It is then possible that women who reduced smoking as a result of their 
engagement in smoking treatment were increasingly benefitted by the bupropion 
component of treatment as treatment continued (i.e., equally reduced cigarette use in 
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the second phase of treatment). As noted above, tailored treatment assignment in the 
second phase of treatment may have additionally been related to increased smoking 
success across participant groups in the second phase of treatment.  
There were no independent or moderating effects of social support on smoking 
outcome variables. This could be related to the socially complex nature of HIV/AIDS. As 
a result of social stigma associated with HIV status, PLWHA are less likely to disclose 
their status to friends and family (Sayles et al., 2007). This may indicate less access to 
instrumental and emotional support for challenges PLWHA uniquely face, even if 
reports of broad social support are high among this group. That is to say, PLWHA may 
experience lower-quality social support even when support is present. Findings are 
congruent with research showing weak associations between social support and health 
among PLWHA (Ironsen et al., 2005; Ironson & Hayward, 2008). However, rather than 
indicating reduced need for social support among smokers living with HIV/AIDS, 
findings support the notion that different forms of support, for instance peer support, 
may be particularly important among this group. Literature has shown effective peer-
based interventions for depressive symptoms among PLWHA with high levels of 
substance use (Simoni, Pantalone, Plummer, & Huang, 2007).  
Implications  
 Based on the relationship between community violence and quitting motivations, 
and intimate partner violence and cigarette use, it is important to assess interpersonal 
and community violence exposure among smokers prior to cessation treatment. This is 
specifically important among smokers with HIV/AIDS, as base rates of violence and 
trauma are greater among this population (Matchinger, Wilson, Haberer, & Weiss, 
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2012). Every individual in the current sample reported community violence exposure, 
with the most prevalently endorsed experiences including witnessing police arrests, 
hearing gunfire, witnessing drug use and drug deals in the neighborhood, and 
witnessing and personally experiencing physical assault (Table 11). The least 
prevalently experienced community violence events (e.g., experiencing threats of being 
stabbed, or killed, and witnessing someone get shot or stabbed in the home) were still 
endorsed by 15-30% of the sample.  
 Although fewer participants endorsed partner violence exposure (potentially 
partially due to the necessity of having had a recent romantic partnership), the majority 
of the sample (60%) still reported violence victimization enacted by intimate partners in 
the past year (Table 12). The most prevalently reported items included experiences of 
being verbally (i.e., insulted, swore, or shouted at) assaulted, and physically injured 
(e.g., experiencing a sprain, bruise, small cut, or physical pain after an altercation). 
Relatively “severe” partner violence experiences were endorsed by 10% of the sample, 
and included needing medical attention after an altercation, being forced (through 
hitting, holding down, or use of a weapon) to have sex, and being forced to have sex 
without a condom (without physical force). Severe sexually violent experiences may be 
directly related to HIV disease status, and thus potentially traumatizing on several 
levels.  
Sixty-eight percent of the sample reported perpetrating violence on intimate 
partners in the past year (Table 13). Prevalence rates of specific perpetration events 
were comparable to the prevalence of victimization events. The most prevalently 
reported perpetration event was insulting, swearing, shouting, or yelling at an intimate 
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partner (65%). Relatively severe violence perpetration experiences were endorsed by 
10-12.5% of the sample. 
For smokers reporting high levels of intimate partner violence exposure, 
therapeutic attention should be given to adaptive coping (Brady et al., 2009; Crane, 
Hawes, & Weinberger, 2013). Two forms of adaptive coping in particular, behavioral 
coping (e.g., problem solving), and cognitive coping (e.g., positive reappraisals), have 
been found to mitigate the influence of violence victimization on substance use (Brady 
et al.). For individuals with significant community violence experience, intrinsic 
motivations to reduce or abstain from smoking should be evaluated. Motivational 
interviewing is one evidence-based approach that would address conscious and 
unconscious motivations to fully engage in treatment to reduce smoking behaviors (Lai, 
Cahill, Qin, Tang, 2010). The 5As/Rs counseling model used in the clinical trial that 
houses the present study emphasizes motivation and behavioral skills in reducing 
smoking (USPHS), and could additionally be used in a targeted fashion when 
individuals report interpersonal or community violence experiences. 
Based on findings related to different patterns of withdrawal among HIV-positive 
smokers who report greater versus lower depression scores, it is important for clinicians 
to assess psychological distress, particularly depression, prior to engaging smokers in 
smoking cessation treatment. It may also be useful to tailor components of treatment to 
the aversive withdrawal experience PLWHA may uniquely face, particularly at the outset 
of smoking treatment. Interventions that emphasize acceptance and tolerance are 
empirically based approaches to the treatment of substance use among individuals with 
mood symptoms (Brewer, Bowen, Smith, Marlatt, & Potenza, 2010; Dimeff & Linehan, 
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2008; Linehan et al., 2002). This is particularly relevant given increased reports of mood 
disorders among PLWHA (Ferrando & Freyberg, 2008; Reynolds, 2009). 
Limitations 
 Findings should be considered in the context of study limitations. The study’s 
sample size (n = 40) was small, limiting the detection of the full strength of relationships 
among violence, mood, life satisfaction, social support, and smoking cessation 
indicators. The sample was also unevenly distributed across gender and ethnic groups, 
with more men (n = 25) than women, and most participants identifying as African-
American (n = 38). In addition, this sample included no individuals that identified as a 
gender other than man or woman. These distributions are particularly important when 
assessing experiences that are known to vary by gender and ethnicity, including 
exposure to community violence and intimate partner violence (Foster, Kuperminc, & 
Price, 2004; Saewyc et al., 2009). It will be important to test the present hypotheses 
with a larger, more equally distributed sample in order to provide firmer basis for the 
present study’s clinical implications. A larger, evenly distributed sample would also allow 
for a deeper analysis of the specific subcomponents of community violence, intimate 
partner violence, and social support that tobacco-using PLWHA may uniquely report.  
An additional limitation as previously specified was the inability to control for 
Phase 2 treatment condition assignment in analyses of Phase 2 treatment outcomes. 
This was due to the confounding nature of Phase 2 assignment with Phase 1 treatment 
response. Finally, this study relies on self-report to measure constructs that may be 
particularly influenced by social desirability (e.g., partner violence, community violence, 
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social support). Of note, self-reported cigarette use behaviors (through TLFB-C) were 
compared to, and congruent with, urinary cotinine levels. 
Directions for Future Research 
 Future research should assess mechanisms underlying relationships between 
community and interpersonal violence and smoking indicators. Specifically, research 
should explore mediational relationships between cognitive and emotional helplessness 
and reduced motivations for quitting smoking. In a larger sample, it would also be 
relevant to examine subcomponents of each form of violence. It is possible that physical 
versus emotional partner violence indicates different outcomes for smoking, particularly 
given that HIV status may be more related to a particular form of partner violence 
(Burke, Thieman, Gielen, O’Campo, & McDonnell, 2005; Maman et al., 2002). The 
Conflict Tactics Scale used in the present analyses has the capacity in a large, 
distributed sample to assess physical versus emotional conflict, frequency, severity, and 
perpetrator experience. Future research could additionally stratify a large sample by 
gender and sexual orientation to examine whether differential patterns of violence 
exposure hold among subsamples of gender and orientation. 
Conclusions 
 This dissertation is an important exploration of the impact of violence, mood, and 
protective factors on smoking cessation experience in a modest sample of HIV-positive 
smokers undergoing smoking cessation treatment. This study’s findings revealed 
important linkages between community violence exposure and motivations for quitting 
smoking, as well as between increased depressive symptoms and patterns of smoking 
withdrawal among HIV-positive smokers. Findings also provided prevalence data on 
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various violence events experienced in the community and within intimate partnerships. 
Continued investigations into risk and protective factors would deepen clinical insight 
and knowledge about therapeutic approaches for a population of smokers with 
heightened clinical and medical risk.   
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Table 1 
Descriptive Statistics 
Study Variables Mean (SD) Percentage Sample Size 
Socio-demographic Variables    
Age 
Gender 
46.95 (9.81) 
 
 40 
40 
    Male  62.5 25 
    Female  37.5 15 
Ethnicity    
    African-American  95 38 
    Caucasian  2.5 1 
    Hispanic 
Education (years) 
Nicotine Dependence 
Treatment Assignment 
    Standard 
    Contingency Management 
 
12.15 (1.42) 
5.50 (1.97) 
 
 
 
2.5 
67.5 
 
 
55.0 
45.0 
1 
40 
40 
39 
22 
18 
 
Predictor Variables    
Community Violence 
Intimate Partner Violence 
28.25 (13.11) 
15.60 (14.30) 
 40 
40 
BDI 15.10 (12.41)  40 
Quality of Life 13.75 (21.61)  40 
Social Support 121.20 (22.00)  40 
 
Outcome Variables 
Cotinine Intake 
 
5.63 (.93) 
  
40 
Cotinine Change Time 1 .50 (.18)  40 
Cotinine Change Time 2 
Cigarette Use Intake 
Cigarette Use Change Time 1 
Cigarette Use Change Time 2 
MNWS Intake 
.55 (.20) 
13.97 (1.09) 
8.29 (.91) 
9.12 (1.12) 
20.33 (15.88) 
 40 
40 
40 
40 
40 
MNWS Change Time 1 
MNWS Change Time 2 
QSU Intake 
4.00 (1.92) 
3.98 (2.06) 
45.95 (15.37) 
 40 
40 
40 
QSU Change Time 1 
QSU Change Time 2 
RFQ Intake 
RFQ Change Time 1 
RFQ Change Time 2 
LDA 
21.33 (2.66) 
22.35 (2.66) 
42.90 (15.72) 
-1.65 (1.92) 
.43 (2.64) 
10.43 (16.56) 
 40 
40 
40 
40 
40 
40 
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Table 2 
Bivariate Correlations 
Primary Variables 1 2 3 4 5 6 7 8 9 10 11 12  13 14 15 16 
1 Comm.Violence  .03 .40* -.16 -.24 -.10 -.10 -.01 -.01 .18 .12 -.10 -.02 .38* .22 -.07 
2 Partn. Violence   .10 -.21 -.03 .09 .06 -.37* -.18 .11 .05 -.13 -.18 .10 -.17 -.14 
3 BDI    -.50** -.47** -.16 -.09 .06 .04 .39* .38* -.04 -.09 .23 .08 -.04 
4 Quality of Life     .55*** .12 .03 -.11 -.14 -.16 -.08 .23 .24 .01 -.09 -.10 
5 Social Support      .17 -.02 -.03 -.15 -.22 -.25 .17 .09 -.08 -.22 .12 
6 Cot. Change T1       .68*** .37* .31 .11 .00 .27 .25 -.02 .07 .49** 
7 Cot. Change T2        .08 .09 .03 -.03 .16 .14 -.08 .10 .46** 
8 Cig. Use Ch T1         .83*** .25 .15 .35* .20 .02 .03 .46** 
9 Cig. Use Ch T2          .23 .13 .33* .16 -.22 -.14 .47** 
10 MNWS Ch T1           .89*** .00 .00 .10 .02 .18 
11 MNWS Ch T2            -.06 .05 .08 .04 .04 
12 QSU Ch T1             .75*** -.20 -.29 .23 
13 QSU Ch T2              -.33* -.26 .15 
14 RFQ Ch T1               .58** -.34* 
15 RFQ Ch T2                -.23 
16 LDA                 
Note. *p < .05; **p < .01; ***p < .001. All outcome scores reported are change scores calculated 
from Intake scores. 
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Table 3 
Multivariate Regression Effects of Violence on Time 1 Smoking Cessation Change 
Scores 
Predictor Variable Beta SE t p R2 (F) 
Explaining cotinine 
scores 
     
Block 1      
   Community violence -.10 .01 -.62 .54  
   Partner violence .09 .01 .55 .58  
Block 2       
   Community violence -.06 .02 -.30 .77  
   Partner violence .21 .02 1.01 .32  
   Age -.34 .02 -1.78 .08  
   Gender -.13 .44 -.68 .50  
   Education -.14 .16 -.70 .49  
   Initial treatment .19 .41 1.08 .29  
   Nicotine dependence .23 .11 1.18 .25  
Explaining cigarette 
use 
     
Block 1       
   Community violence .02 .07 .02 .98  
   Partner violence -.37 .06 -2.46 .02  
Block 2       
   Community violence -.05 .07 -.33 .74  
   Partner violence -.10 .07 -2.32 .04  
   Age .11 .10 .63 .53  
   Gender -.33 1.90 -2.03 .05  
   Education -.26 .69 -1.54 .13  
   Initial treatment  .20 1.79 1.26 .22  
   Nicotine dependence .19 .49 1.10 .28  
.14 (6.07)* 
Explaining withdrawal  
Block 1       
   Community violence .18 .15 1.11 .27  
   Partner violence .10 .14 .63 .54  
Block 2       
   Community violence .25 .18 1.32 .20  
   Partner violence .22 .18 1.03 .31  
   Age .02 .25 .09 .93  
   Gender .03 4.74 .06 .95  
   Education -.24 1.73 -1.17 .25  
   Initial treatment .01 4.47 .06 .95  
   Nicotine dependence .02 1.23 .11 .91  
Explaining urges  
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Block 1       
   Community violence -.09 .21 -.53 .60  
   Partner violence -.13 .19 -.79 .44  
Block 2       
   Community violence -.11 .24 -.58 .57  
   Partner violence -.04 .25 -.17 .87  
   Age .15 .34 .76 .45  
   Gender -.13 6.54 -.67 .51  
   Education -.17 2.39 -.83 .41  
   Initial treatment  -.07 6.18 -.39 .87  
   Nicotine dependence  -.08 1.70 -.40 .69  
Explaining motivations  
for quitting smoking 
 
Block 1       
   Community violence .38 .14 2.49 .02  
   Partner violence .09 .13 .61 .55  
Block 2       
   Community violence .29 .16 1.92 .04  
   Partner violence .08 .17 .38 .70  
   Age .02 .23 .12 .90  
   Gender -.20 4.44 -1.09 .28  
   Education .11 1.62 .60 .55  
   Initial treatment  -.03 4.19 -.16 .87  
   Nicotine dependence .06 1.16 .33 .74  
     .15 (3.34)* 
Note. *p < .05; **p < .01; ***p < .001. All outcome scores reported are change scores from 
intake to Time 1. Standardized beta (β) coefficients and unstandardized standard error (SE) 
coefficient values are reported. Final R2 and F statistics are reported for significant models.  
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Table 4 
Multivariate Regression Effects of Violence on Time 2 Smoking Cessation Change 
Scores 
Predictor Variable Beta SE t p R2 (F) 
Explaining cotinine 
scores 
     
Block 1      
   Community violence -.11 .02 -.64 .52  
   Partner violence .06 .02 .38 .71  
Block 2       
   Community violence -.08 .02 -.40 .69  
   Partner violence .19 .02 .88 .39  
   Age -.11 .03 -.54 .59  
   Gender -.01 .50 -.01 .10  
   Education -.14 .18 -.68 .50  
   Initial treatment .25 .47 1.33 .19  
   Nicotine dependence -.01 .13 -.04 .97  
Explaining cigarette 
use 
     
Block 1       
   Community violence .01 .09 .08 .94  
   Partner violence -.18 .08 -1.11 .27  
Block 2       
   Community violence -.03 .09 -.18 .86  
   Partner violence .14 .09 .79 .44  
   Age .20 .12 1.19 .24  
   Gender -.33 2.39 -1.99 .06  
   Education -.34 .87 -1.97 .06  
   Initial treatment  .13 2.25 .83 .41  
   Nicotine dependence .22 .62 1.26 .22  
Explaining withdrawal  
Block 1       
   Community violence .12 .16 .73 .47  
   Partner violence .05 .15 .30 .77  
Block 2       
   Community violence .22 .19 1.19 .24  
   Partner violence .08 .19 .38 .71  
   Age .01 .26 .07 .94  
   Gender .11 5.06 .59 .56  
   Education -.17 1.84 -.85 .40  
   Initial treatment -.16 4.78 -.89 .38  
   Nicotine dependence .15 1.32 .75 .46  
Explaining urges  
Block 1       
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   Community violence -.09 .21 -.11 .91  
   Partner violence -.18 .19 -1.12 .27  
Block 2       
   Community violence .05 .24 .25 .81  
   Partner violence -.18 .25 -.86 .39  
   Age -.17 .35 -.85 .40  
   Gender .07 6.62 .35 .73  
   Education -.07 2.41 -.37 .72  
   Initial treatment  .01 6.23 .05 .96  
   Nicotine dependence  .02 1.72 .09 .93  
Explaining motivations  
for quitting smoking 
 
Block 1       
   Community violence .23 .20 1.46 .15  
   Partner violence -.18 .18 -1.12 .27  
Block 2       
   Community violence .30 .23 1.65 .11  
   Partner violence -.18 .24 -.88 .39  
   Age -.06 .33 -.32 .75  
   Gender .12 6.28 .66 .51  
   Education -.01 2.29 -.01 .99  
   Initial treatment  .01 5.93 .01 .10  
   Nicotine dependence .23 1.63 1.18 .25  
Explaining LDA  
Block 1       
   Community violence -.06 .21 -.38 .71  
   Partner violence -.13 .19 -.82 .42  
Block 2       
   Community violence .01 .22 .08 .94  
   Partner violence .14 .22 .73 .47  
   Age -.03 .31 -.14 .89  
   Gender .06 5.88 .31 .76  
   Education -.37 2.14 -1.99 .06  
   Initial treatment  .40 5.55 2.38 .02  
   Nicotine dependence -.11 1.53 -.58 .57  
Note. *p < .05; **p < .01; ***p < .001. All outcome scores reported are change scores from 
intake to Time 2. Standardized beta (β) coefficients and unstandardized standard error (SE) 
coefficient values are reported. Final R2 and F statistics are reported for significant models.  
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Table 5 
Multivariate Regression Effects of Mood and Life Quality on Time 1 Smoking Cessation 
Change Scores 
Predictor Variable Beta SE t p R2 (F) 
Explaining cotinine       
Block 1      
   Depressive symptoms -.14 .02 -.72 .48  
   Quality of life .06 .01 .30 .77  
Block 2       
   Depressive symptoms -.05 .02 -.23 .82  
   Quality of life .04 .01 .21 .84  
   Age -.34 .02 -1.69 .10  
   Gender -.07 .42 -.42 .70  
   Education -.05 .14 -.32 .75  
   Initial treatment .12 .40 .69 .49  
   Nicotine dependence .21 .12 1.02 .32  
Explaining cigarette use      
Block 1       
   Depressive symptoms .01 .09 .03 .98  
   Quality of life -.10 .05 -.54 .59  
Block 2       
   Depressive symptoms .09 .08 .51 .61  
   Quality of life -.08 .04 -.45 .65  
   Age .07 .10 .38 .71  
   Gender -.33 1.76 -2.18 .04  
   Education -.33 .58 -2.28 .03  
   Initial treatment  .24 1.71 1.60 .12  
   Nicotine dependence .22 .51 1.29 .21  
.36 (2.58)* 
Explaining withdrawal  
Block 1       
   Depressive symptoms .41 .17 2.33 .03  
   Quality of life .05 .10 .27 .79  
Block 2       
   Depressive symptoms .46 .19 2.35 .03  
   Quality of life .06 .11 .29 .77  
   Age -.08 .24 -.43 .67  
   Gender .03 4.22 .02 .99  
   Education -.10 1.39 -.60 .56  
   Initial treatment .05 4.10 .27 .79  
   Nicotine dependence .12 1.21 .62 .54  
     .15 (3.27)* 
Explaining urges  
Block 1       
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   Depressive symptoms .10 .25 .52 .61  
   Quality of life .28 .14 1.50 .14  
Block 2       
   Depressive symptoms .06 .27 .28 .79  
   Quality of life .28 .15 1.45 .16  
   Age .19 .34 .93 .36  
   Gender -.09 5.10 -.54 .59  
   Education -.20 1.96 -1.21 .23  
   Initial treatment  -.09 5.79 -.53 .59  
   Nicotine dependence  -.07 1.71 -.34 .73  
Explaining motivations  
for quitting smoking 
 
Block 1       
   Depressive symptoms .31 .18 1.70 .10  
   Quality of life .17 .10 .90 .37  
Block 2       
   Depressive symptoms .29 .19 1.49 .15  
   Quality of life .18 .11 .94 .36  
   Age .01 .24 .04 .97  
   Gender -.26 4.20 -1.54 .13  
   Education .22 1.38 1.34 .19  
   Initial treatment  .00 4.08 .03 .98  
   Nicotine dependence .11 1.20 .58 .57  
Note. *p < .05; **p < .01; ***p < .001. All outcome scores reported are change scores from 
intake to Time 1. Standardized beta (β) coefficients and unstandardized standard error (SE) 
coefficient values are reported. Final R2 and F statistics are reported for significant models.  
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Table 6 
Multivariate Regression Effects of Mood and Life Quality on Time 2 Smoking Cessation 
Change Scores 
Predictor Variable Beta SE t p R2 (F) 
Explaining cotinine       
Block 1      
   Depressive symptoms -.10 .20 -.52 .61  
   Quality of life -.03 .01 -.13 .90  
Block 2       
   Depressive symptoms -.06 .02 -.26 .79  
   Quality of life -.04 .01 -.20 .84  
   Age -.12 .03 -.58 .57  
   Gender .05 .48 .29 .78  
   Education -.07 .16 -.41 .68  
   Initial treatment .19 .46 1.03 .31  
   Nicotine dependence -.03 .14 -.12 .90  
Explaining cigarette use      
Block 1       
   Depressive symptoms -.04 .11 -.22 .83  
   Quality of life .16 .06 .85 .40  
Block 2       
   Depressive symptoms .02 .10 .10 .92  
   Quality of life -.12 .06 -.71 .48  
   Age .16 .13 .92 .36  
   Gender -.30 2.24 -1.93 .06  
   Education -.30 .73 -1.99 .06  
   Initial treatment  .11 2.17 .71 .49  
   Nicotine dependence .22 .64 1.25 .22  
Explaining withdrawal  
Block 1       
   Depressive symptoms .46 .18 2.64 .01  
   Quality of life .16 .11 .89 .38  
Block 2       
   Depressive symptoms .54 .20 2.89 .01  
   Quality of life .19 .11 1.06 .30  
   Age -.08 .25 -.41 .68  
   Gender .07 4.32 .43 .67  
   Education -.10 1.42 -.64 .53  
   Initial treatment -.10 4.20 -.59 .56  
   Nicotine dependence .28 1.24 1.47 .15  
     .16 (3.62)* 
Explaining urges  
Block 1       
   Depressive symptoms .04 .25 .23 .82  
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   Quality of life .26 .14 1.39 .17  
Block 2       
   Depressive symptoms .08 .28 .39 .70  
   Quality of life .25 .15 1.24 .23  
   Age -.13 .35 .27 .79  
   Gender .03 6.14 .16 .88  
   Education -.14 2.01 -.81 .43  
   Initial treatment  .05 5.97 .27 .79  
   Nicotine dependence  .04 1.76 .18 .86  
Explaining motivations  
for quitting smoking 
 
Block 1       
   Depressive symptoms .04 .26 .21 .84  
   Quality of life -.07 .15 -.36 .72  
Block 2       
   Depressive symptoms .14 .28 .65 .52  
   Quality of life -.03 .15 -.16 .87  
   Age -.06 .35 -.31 .76  
   Gender .00 6.14 .02 .99  
   Education -.01 2.01 -.08 .94  
   Initial treatment  .10 5.97 .54 .59  
   Nicotine dependence .26 1.76 1.23 .23  
Explaining LDA  
Block 1       
   Depressive symptoms -.12 .25 -.65 .52  
   Quality of life -.16 .14 -.86 .40  
Block 2       
   Depressive symptoms -.06 .25 -.29 .77  
   Quality of life -.19 .14 -1.03 .31  
   Age -.06 .31 -.30 .77  
   Gender .07 5.47 .43 .67  
   Education -.31 1.79 -1.98 .06  
   Initial treatment  .38 5.3 2.33 .03  
   Nicotine dependence -.12 1.57 -.65 .52  
Note. *p < .05; **p < .01; ***p < .001. All outcome scores reported are change scores from 
intake to Time 2. Standardized beta (β) coefficients and unstandardized standard error (SE) 
coefficient values are reported. Final R2 and F statistics are reported for significant models.  
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Table 7 
Moderating Effects of Social Support on the Relationship between Violence and Time 1 
Change in Cigarette Use 
Predictor Variable Beta SE t p R2 (F) ∆F 
Community violence       
Block 1       
   Social support -.02 .07 -.11 .91   
   Community violence -.04 .04 -.22 .83   
     .01 .03 
Block 2        
   Social support -.02 .04 -.13 .90   
   Community violence -.06 .07 -.34 .73   
   Age .11 .10 .66 .52   
   Gender -.34 1.87 -2.15 .04   
   Education -.30 .61 -1.99 .06   
   Initial treatment .22 1.75 1.46 .15   
   Nicotine dependence .19 .50 1.10 .28   
     .34 (2.40)* 3.35* 
Block 3       
   Social support -.48 .13 -1.00 .32   
   Community violence -1.02 .42 -1.06 .30   
   Age .08 .10 .46 .65   
   Gender -.37 1.89 -2.27 .03   
   Education -.30 .61 -1.98 .06   
   Initial treatment .25 1.77 1.60 .12   
   Nicotine dependence .18 .50 1.04 .31   
   Soc. support by Comm. violence .96 .00 1.01 .32   
     .37 (2.23)* 1.03 
Intimate partner violence       
Block 1       
   Social support -.04 .04 -.27 .79   
   Intimate partner violence -.37 .06 -2.44 .02   
     .14 (2.10) 2.10 
Block 2        
   Social support -.01 .04 -.05 .10   
   Intimate partner violence -.09 .07 -.49 .62   
   Age .10 .10 .60 .56   
   Gender -.31 1.83 -1.10 .04   
   Education -.28 .67 -1.67 .11   
   Initial treatment .19 1.81 1.23 .23   
   Nicotine dependence .19 .50 1.11 .28   
     .35 (2.43)* 2.03 
Block 3       
   Social support -.23 .06 -.95 .35   
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   Intimate partner violence -1.16 .38 -1.24 .22   
   Age .11 .10 .64 .53   
   Gender -.32 1.82 -2.08 .04   
   Education -.27 .67 -1.63 .11   
   Initial treatment .20 1.81 1.28 .21   
   Nicotine dependence .17 .50 1.01 .32   
   Soc. support by Part. violence 1.10 .00 1.17 .25   
     .37 (2.32)* 1.36 
Note. *p < .05; **p < .01; ***p < .001. All outcome scores reported are change scores from intake to 
Time 1. Standardized beta (β) coefficients and unstandardized standard error (SE) coefficient values 
are reported. R2, F, and F change statistics are reported.  
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Table 8 
Moderating Effects of Social Support on the Relationship between Depressive Symptoms and 
Time 1 Change in Withdrawal 
 
Predictor Variable Beta SE t p R2 (F) ∆F 
Depressive Symptoms       
Block 1       
   Social support -.05 .10 -.30 .77   
   Depressive symptoms .36 .17 2.10 .04   
     .15 (3.28)* 3.28* 
Block 2        
   Social support -.02 .11 -.11 .92   
   Depressive symptoms .43 .19 2.14 .04   
   Age -.09 .24 -.44 .66   
   Gender .01 4.24 .02 .99   
   Education -.10 1.39 -.59 .56   
   Initial treatment .05 4.13 .29 .78   
   Nicotine dependence .11 1.25 .55 .59   
     .17 (.95) .17 
Block 3       
   Social support -.32 .21 -.81 .42   
   Depressive symptoms -.42 .96 -.42 .68   
   Age -.13 .25 -.64 .53   
   Gender -.06 4.58 -.30 .76   
   Education -.11 1.40 -.68 .50   
   Initial treatment .05 4.15 .27 .79   
   Nicotine dependence .14 1.27 .68 .51   
   Soc. support by Dep. Symptoms .77 .01 .88 .39   
     .19 (.93) .77 
Note. *p < .05; **p < .01; ***p < .001. All outcome scores reported are change scores from intake to 
Time 1. Standardized beta (β) coefficients and unstandardized standard error (SE) coefficient values 
are reported. R2, F, and F change statistics are reported.  
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Table 9 
Moderating Effects of Social Support on the Relationship between Depressive Symptoms/Life 
Satisfaction and Time 1 Change in Cigarette Use 
 
Predictor Variable Beta SE t p R2 (F) ∆F 
Depressive Symptoms       
Block 1       
   Social support -.01 .05 -.04 .97   
   Depressive symptoms .05 .09 .29 .78   
     .01 (.06) .06 
Block 2        
   Social support .08 .04 .45 .66   
   Depressive symptoms .17 .08 .95 .35   
   Age .06 .10 .36 .72   
   Gender -.33 1.77 -2.20 .04   
   Education -.33 .58 -2.30 .03   
   Initial treatment .23 1.72 1.53 .14   
   Nicotine dependence .25 .52 1.41 .17   
     .36 (2.57)* 3.57* 
Block 3       
   Social support -.16 .09 -.48 .64   
   Depressive symptoms -.51 .40 -.59 .56   
   Age .03 .11 .15 .88   
   Gender -.38 1.91 -2.33 .03   
   Education -.34 .59 -2.35 .03   
   Initial treatment .23 1.74 1.50 .14   
   Nicotine dependence .28 .53 1.51 .14   
   Soc. support by Dep. Symptoms       
     .37 (2.31)* .64 
Life satisfaction       
Block 1       
   Social support .04 .05 .19 .85   
   Life satisfaction -.13 .05 -.64 .53   
     .01 (.22) .22 
Block 2        
   Social support .09 .05 .50 .62   
   Life satisfaction -.17 .05 -.95 .35   
   Age .07 .10 .44 .66   
   Gender -.34 1.78 -2.24 .03   
   Education -.33 .58 -2.29 .03   
   Initial treatment .22 1.72 1.45 .16   
   Nicotine dependence .21 .50 1.26 .22   
     .36 (2.57)* 3.48* 
Block 3       
   Social support .08 .05 .47 .64   
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   Life satisfaction .66 .24 .75 .46   
   Age .04 .10 .24 .81   
   Gender -.38 1.84 -2.40 .02   
   Education -.35 .59 -2.43 .02   
   Initial treatment .22 1.72 1.46 .16   
   Nicotine dependence .24 .50 1.40 .17   
   Soc. support by Life satisfaction -.85 .01 -.95 .35   
     .38 (2.36)* .90 
Note. *p < .05; **p < .01; ***p < .001. All outcome scores reported are change scores from intake to 
Time 1. Standardized beta (β) coefficients and unstandardized standard error (SE) coefficient values 
are reported. Final R2, F, and F change statistics are reported.  
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Table 10 
Moderating Effects of Social Support on the Relationship between Depressive Symptoms and 
Time 2 Change in Withdrawal 
 
Predictor Variable Beta SE t p R2 (F) ∆F 
Depressive Symptoms       
Block 1       
   Social support -.09 .10 -.54 .60   
   Depressive symptoms .34 .18 1.97 .04   
     .15 (3.32)* 3.32* 
Block 2        
   Social support -.01 .11 -.07 .94   
   Depressive symptoms .44 .20 2.28 .03   
   Age -.09 .25 -.47 .65   
   Gender .07 4.41 .40 .69   
   Education -.10 1.44 -.65 .52   
   Initial treatment -.09 4.29 -.55 .59   
   Nicotine dependence .25 1.30 1.28 .21   
     .22 (1.32) .60 
Block 3       
   Social support -.36 .22 -.97 .34   
   Depressive symptoms -.55 .99 -.58 .57   
   Age -.14 .26 -.72 .48   
   Gender -.01 4.73 -.02 .98   
   Education -.12 1.45 -.76 .46   
   Initial treatment -.10 4.29 -.57 .57   
   Nicotine dependence .29 1.31 1.44 .16   
   Soc. support by Dep. Symptoms .91 .01 1.07 .29   
     .25 (1.31) 1.14 
Note. *p < .05; **p < .01; ***p < .001. All outcome scores reported are change scores from intake to 
Time 1. Standardized beta (β) coefficients and unstandardized standard error (SE) coefficient values 
are reported. Final R2, F, and F change statistics are reported. 
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Table 11 
Selected Item Endorsements of Community Violence Exposure on Things I Have Seen 
and Heard 
 
Prevalence (%) 
Item At least once Never 
Heard guns being shot 87.5 12.5 
Seen somebody arrested 90 10 
Seen drug deals 82.5 17.5 
Seen somebody being beat up 82.5 17.5 
Been beaten up 62.5 37.5 
Seen somebody get stabbed 42.5 57.5 
Seen somebody get shot 55 45 
Seen a gun in my home (not my own gun) 35 65 
Seen drugs/drug paraphernalia (items used to administer 
drugs) in my neighborhood 
85 15 
Somebody threatened to kill me 30 70 
Seen a dead body outside 45 55 
Somebody threatened to shoot me 35 65 
Somebody threatened to stab me 30 70 
Seen somebody in my home get shot or stabbed 15 85 
Note. One-hundred percent of participants reported at least one community violence event. 
Above items represent selected items from the Things I Have Seen and Heard. Reverse-scored 
items are not presented.  
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Table 12 
Selected Item Endorsements of Intimate Partner Violence Victimization on Revised 
Conflict Tactics Scale 
  Past-year Prevalence (%) 
Item At least once Never 
My partner insulted or swore or shouted or yelled at me 57.5 42.5 
Had a sprain, bruise, or small cut, or felt pain the next day 
because of a fight with my partner 
20 80 
My partner pushed, shoved, or slapped me 17.5 82.5 
My partner punched or kicked or beat me up 15 85 
My partner destroyed something belonging to me or threatened 
to hit me 
12.5 87.5 
Went see a doctor (M.D.) or needed to see a doctor because of 
a fight with my partner 
10 90 
My partner used force (like hitting, holding down, or using a 
weapon) to make me have sex  
10 90 
My partner insisted on sex when I did not want to or insisted on 
sex without a condom (but did not use physical force) 
10 90 
Note. Sixty percent of participants reported at least one intimate partner violence victimization 
event. Above items are violence victimization items from Revised Conflict Tactics Scale (Short 
Form) presented in order of item severity.  
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Table 13 
Selected Item Endorsements of Intimate Partner Violence Perpetration on Revised 
Conflict Tactics Scale 
  Past-year Prevalence (%) 
Item At least once Never 
I insulted or swore or shouted or yelled at my partner 65 35 
My partner had a sprain, bruise, or small cut, or felt pain the 
next day because of a fight with me 
17.5 82.5 
I pushed, shoved, or slapped my partner 20 80 
I punched or kicked or beat up my partner 10 90 
I destroyed something belonging to my partner or threatened to 
hit my partner 
20 80 
My partner went see a doctor (M.D.) or needed to see a doctor 
because of a fight with me 
10 90 
I used force (like hitting, holding down, or using a weapon) to 
make my partner have sex  
12.5 87.5 
I insisted on sex when my partner did not want to, or insisted 
on sex without a condom (but did not use physical force) 
10 90 
Note. Sixty-eight percent of participants reported at least one intimate partner violence 
perpetration event. Above items are violence perpetration items from Revised Conflict Tactics 
Scale (Short Form) presented in order of item severity.  
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Table 14 
 
Mean Reports of Life Satisfaction in 17 Areas of Life Functioning  
 
Life Area Mean SD 
Standard of Living 0.05 1.10 
Work 0.08 1.99 
Health 0.20 1.76 
Neighborhood 0.33 1.85 
Civic Action 0.45 1.95 
Community 0.58 1.77 
Recreation 0.67 1.88 
Creativity 0.83 1.85 
Love Relationships 0.85 2.06 
Home 0.90 1.85 
Self-regard 1.03 1.69 
Learning 1.13 1.61 
Philosophy of Life 1.18 1.52 
Relationships with Relatives 1.23 1.75 
Social Service 1.25 1.66 
Friendships 1.48 1.72 
Relationships with Children 1.60 1.50 
Total score  13.75 21.61 
Note. Items are from the Quality of Life Inventory, presented in ascending order of satisfaction 
(i.e., lowest mean satisfaction scores to highest). Items are scored on a scale from -3 to 3, with 
higher scores indicate greater life satisfaction.   
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Figure 1 
Reductions in Nicotine Withdrawal by High/Low Depression Scores 
 
 
Note. Group means differed significantly at each time point at the following levels: *p < .05; **p < 
.01; ***p < .001. Post-Phase 1 and Post-Phase 2 values represent raw values (not change-
scores) at each time point. Change score values at each time point also differed significantly 
between high and low depression scorers.  
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The rate of cigarette smoking is three-fold higher among adults living with Human 
Immunodeficiency Virus (HIV)/Autoimmune Deficiency Syndrome (AIDS) than in the 
general population (Centers for Disease Control and Prevention, 2015). Relative to non-
smoking HIV-positive adults, HIV-positive cigarette smokers have even higher mortality 
rates, more physical health problems, greater tobacco-related health disparities, lower 
quality of life, and more barriers to treatment. These barriers are often interrelated with 
the significantly higher rate of trauma and violence exposure reported in both cigarette 
smokers and persons living with HIV/AIDS (PLWHA; CDC). Violence exposure not only 
predicts emotional distress and substance use, but also mediates between victimization 
and cigarette use (e.g., Feldner, Babson, & Zvolensky, 2007). Psychological and 
physical trauma additionally impact both short and long-term substance use treatment 
outcomes, independent of treatment modality (e.g., Ford et al., 2007). Though social 
support is consistently linked to both smoking behaviors, and mental and behavioral 
outcomes for PLWHA, few studies have examined the role of social support in smoking 
treatment among this population. Additionally, no studies have explored social and 
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individual-level protective and risk factors in the context of a contingency management 
smoking cessation treatment design. The aim of this study was to examine how different 
risk and protective factors affect cessation outcomes among PLWHA undergoing 
contingency-based treatment for cigarette smoking. Specifically, this study explored 
how different components of violence (community and interpersonal partner violence), 
distress, life satisfaction, and social support affect cigarette use and cessation success. 
Study findings showed that intimate partner violence predicted increased initial change 
in cigarette use, while community violence predicted reduced initial motivations for 
quitting smoking. Increased depression scores predicted both initial and total treatment 
change in withdrawal experience. Findings have implications for the assessment of and 
therapeutic approaches to smoking cessation for smokers living with HIV/AIDS. 
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